Application of a whole-process targeting molecule and its drug complex in constructing a drug delivery system

By covalently connecting brain-targeting molecules with tumor-targeting molecules to form a whole-process targeting molecule, and building modified imaging molecules and therapeutic drug complexes, the problem of drugs passing through the blood-brain barrier and hemotoma barrier is solved, and the problem of drugs passing through the blood-brain barrier and hematologic barrier is achieved Efficient targeted treatment and diagnosis of brain tumors and peripheral tumors, especially the targeting ability of tumor stem cells, has been significantly improved.

CN114981310BActive Publication Date: 2024-12-03FUDAN UNIVERSITY
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
CN202180008713.0
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2020-01-23
Filing Date
2021-01-20
Publication Date
2024-12-03
Estimated Expiration
2041-01-20

AI Technical Summary

Technical Problem

Existing drugs are difficult to effectively pass through the blood-brain barrier and hematologic barrier, resulting in poor brain tumor treatment and insufficient targeting ability to tumor stem cells, making it difficult to reach tumor tissue treatment.

Method used

By covalently connecting brain targeting molecules with tumor targeting molecules to form whole-process targeting molecules, and constructing modified imaging molecules, therapeutic drug complexes and nanomedicine-loading systems, these molecules and systems are used to achieve brain tumors and peripherals. Targeted diagnosis and treatment of tumors.

Benefits of technology

It significantly improved the targeted delivery ability of drugs to brain tumors and peripheral tumors with brain metastases, enhanced the therapeutic effect, and improved the targeted ability of tumor stem cells, and extended the patient's survival time.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN114981310B_ABST
    Figure CN114981310B_ABST
Patent Text Reader

Abstract

The present invention belongs to the field of pharmacy, and discloses a whole-process targeting molecule with targeting brain capillary endothelial cells (across the blood-brain barrier), tumor neovascular endothelial cells (across the blood-tumor barrier), tumor mimic vessels, tumor cells and tumor stem cells, as well as the use of modified drug complexes and nano-drug delivery systems in tumor diagnosis and targeted therapy. The whole-process targeting molecule of the present invention, its drug complex and the nano-drug delivery system constructed therefrom can deliver the carried imaging molecules, therapeutic drugs and nano-drug delivery systems to brain tumor tissues, or to peripheral tumor tissues with brain metastasis characteristics.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS

[0002] This application claims priority to Chinese invention patent application No. CN202010078153.3 filed on January 23, 2020, which is incorporated herein by reference in its entirety. Technical Field

[0003] The present invention belongs to the field of pharmacy, and relates to a whole-process targeting molecule with targeting to brain capillary endothelial cells (across the blood-brain barrier), tumor neovascular endothelial cells (across the blood-tumor barrier), tumor mimic vessels, tumor cells and tumor stem cells, and the use of the modified drug complex and drug delivery system in tumor diagnosis and targeted treatment. The present invention specifically relates to the whole-process targeting molecule and its modified imaging molecule and therapeutic drug complex, the modified targeting functional carrier material and the constructed liposome, polymer micelle, polymer disc, nanoparticle, biofilm-coated nanoformulation and other nano drug delivery systems, and its application in the diagnosis and targeted treatment of brain tumors or peripheral tumors with brain metastasis characteristics. Background Art

[0004] Tumors are serious threats to human life and health, and their mortality rate ranks among the top of all diseases. Among them, the incidence and mortality of primary brain tumors are both in the top 10 of my country's tumor rankings, and gliomas account for about 45% of primary brain tumors. The median survival of patients is less than 16 months, which is extremely harmful. Drug chemotherapy is still the main means of treating brain tumors, but it has defects such as poor selectivity for tumor tissues, high toxicity, narrow therapeutic window, and easy multidrug resistance, and chemotherapy drugs are also extremely limited. In recent years, active targeted drug delivery has become an important strategy to improve the targeting efficiency of brain tumor tissues. The active targeting strategy mainly targets receptors or transporters that are highly expressed in brain tumor tissues, and uses corresponding ligands that have specific recognition and binding capabilities with the receptors or transporters to deliver drugs or drug delivery systems to brain tumor tissues or cells. Most of the current ligands only target a certain receptor or transporter and a certain cell. However, brain tumor tissues not only have tumor cells, but also tumor stem cells, tumor mimic vessels, brain capillaries and their blood-brain barrier (BBB), tumor neovascularization and its blood-tumor barrier (BTB), etc. In the early stage of brain tumor development, the BBB remains intact and restricts the entry of drugs into the brain, making about 98% of small molecule chemotherapy drugs and almost 100% of macromolecular drugs such as proteins unable to enter the brain through the BBB, resulting in almost ineffective drug treatment; as the tumor develops, tumor angiogenesis occurs, but the new blood vessels of brain tumors are relatively dense and have poor permeability compared to peripheral tumors, and the formed BTB becomes the main obstacle to drug delivery, and the existence of BBB in the infiltration area of ​​brain glioma also hinders drug transport; at the same time, brain tumor stem cells have the characteristics of self-renewal, proliferation and high tumorigenicity. Although their number in tumor tissue is extremely small, they show a high tolerance to drug treatment and are prone to recurrence of brain glioma. In view of this, it is crucial to select a targeting molecule that has better ability to cross the BBB and BTB and has better affinity for brain tumors.

[0005] Based on the current state of the art, the inventors of this application further modified the existing targeting molecules, and used the principle of molecular fusion to covalently link the brain targeting molecules with the tumor targeting molecules into full-process targeting molecules, so that they have the full-process targeting function for the growth and development of brain tumors or peripheral tumors with brain metastasis characteristics. At the same time, the imaging molecules and therapeutic drug complexes modified with full-process targeting molecules, the modified targeting function carrier materials and the drug-carrying systems constructed therefrom are constructed, so as to more effectively play the role of imaging diagnosis and targeted treatment of brain tumors or peripheral tumors with brain metastasis characteristics. Summary of the invention

[0006] The purpose of the present invention is to provide a whole-process targeting molecule that targets brain capillary endothelial cells (across BBB), tumor neovascular endothelial cells (across BTB), tumor mimic vessels, tumor cells and tumor stem cells, which is formed by covalently linking brain targeting molecules and tumor targeting molecules. The whole-process targeting molecule is used to modify imaging molecules, therapeutic drugs, and polymer carrier materials to construct a targeting molecule-drug complex and a nano-drug delivery system modified with a targeting molecule, so as to improve the targeted diagnosis and treatment effect of drugs on the brain, brain tumors or peripheral tumors with brain metastasis characteristics.

[0007] The first aspect of the present invention provides a whole-process targeting molecule, which is formed by covalently linking two molecules, a brain targeting molecule and a tumor targeting molecule, and can mediate the targeted delivery of imaging molecules, therapeutic drugs and nano-drug delivery systems;

[0008] The whole-process targeting molecules are composed of targeting molecules such as small molecules, polypeptide molecules or protein molecules that cross the blood-brain barrier and the blood-tumor barrier and target tumor-mimicking blood vessels and tumor cells and their stem cells;

[0009] Preferably, the whole-process targeting molecule can target brain capillary endothelial cells and cross the blood-brain barrier, target tumor neovascular endothelial cells and cross the blood-tumor barrier, and simultaneously target tumor mimicry blood vessels, tumor cells and tumor stem cells;

[0010] More preferably, the whole-process targeting molecule can mediate imaging molecules, therapeutic drugs and nano-drug delivery systems across the blood-brain barrier and the blood-tumor barrier, targeting tumor-mimicking blood vessels, tumor cells and / or tumor stem cells, and achieving targeted delivery of imaging molecules, therapeutic drugs and nano-drug delivery systems to brain tumors and peripheral tumors with brain metastasis characteristics.

[0011] According to the first aspect of the present invention, the whole process targeting molecule, wherein the targeting molecule such as small molecules, polypeptide molecules or protein molecules that cross the blood-brain barrier is selected from: p-hydroxybenzoic acid (pHA) and its derivatives, fatty acids such as myristic acid (MC) and its derivatives, D8 polypeptide, WSW polypeptide, D WSW peptide, TGN peptide, D TGN peptide, CDX peptide, D CDX peptide, T7 peptide and D T7 polypeptide and its derivatives, transferrin, lactoferrin and their derivatives; and / or

[0012] The targeting molecules such as polypeptide molecules or protein molecules that cross the blood-tumor barrier are selected from: VAP polypeptide, cVAP polypeptide, S VAP peptide, D VAP polypeptide, A7R polypeptide, cA7R polypeptide, DA7R polypeptide, RGD polypeptide, Stapled-RGD polypeptide, RW polypeptide, mn polypeptide, RAP12 polypeptide and D RAP12 polypeptide and its derivatives.

[0013] According to the whole process targeting molecule of the first aspect of the present invention, active functional groups can be introduced into the whole process targeting molecule to construct the modified imaging molecule complex, therapeutic drug complex and targeted functional carrier material and its nano drug delivery system. Among them, the imaging molecule X is introduced into the whole process targeting molecule to obtain the whole process targeting molecule-X complex; the therapeutic drug molecule Y is introduced into the whole process targeting molecule to obtain the whole process targeting molecule-Y complex; the polyethylene glycol-Z complex is introduced into the whole process targeting molecule to obtain the whole process targeting molecule-polyethylene glycol-Z complex of the targeted functional carrier material, wherein Z is a lipophilic material molecule or a lipophilic drug molecule or a hydrophilic ligand molecule, and further prepared into a nano drug delivery system with the whole process targeting molecule modified on the surface.

[0014] The second aspect of the present invention provides a drug complex, which is composed of the whole-process targeting molecule and imaging molecule and therapeutic drugs described in the first aspect;

[0015] Preferably, active functional groups are introduced into the whole-process targeting molecule to construct its modified imaging molecule complex and therapeutic drug complex; wherein, imaging molecule X is introduced into the whole-process targeting molecule to obtain the whole-process targeting molecule-X complex; therapeutic drug molecule Y is introduced into the whole-process targeting molecule to obtain the whole-process targeting molecule-Y complex.

[0016] According to the whole-process targeting molecule of the first aspect or the drug complex of the second aspect of the present invention, wherein, in the whole-process targeting molecule-X complex, X is selected from one or more of the following: optical imaging molecules, magnetic resonance imaging agents, radionuclide imaging agents, used for imaging diagnosis and tracing of brain tumors or peripheral tumors;

[0017] Preferably, the optical imaging molecules are selected from one or more of the following: fluorescent probe molecules FITC, FAM, 6-TET, 5-TAMRA, HEX, 6-JOE, near-infrared dye molecules Cy3, Cy3.5, Cy5, Cy5.5, Cy7, IR783, IR820, DiR, DiD, BIDIPY630 / 650-X, BIDIPY650 / 665-X, BIDIPY665 / 676, TO-PRO-3, TO-PRO-5, chemiluminescent molecules luminol, isoluminol, AMPPD, CSPD, CDP-star, lucigenin, Raman probe molecules;

[0018] Preferably, the magnetic resonance imaging agent is a chelate of a Gd magnetic resonance substance; and / or

[0019] Preferably, the radionuclide imaging agent is selected from one or more of the following: 18 F. 32 P. 35 S. 64 Cu, 67 / 68 Ga, 75 Se, 89 Zr, 86 Y. 99m Tc, 111 / 111m In, 123 / 125 I. 177 Lu, 149 / 161 Chelates of radionuclides for Tb imaging;

[0020] More preferably, the magnetic resonance imaging agent and the radionuclide imaging agent are composed of a bifunctional chelating agent and a magnetic resonance imaging substance or an imaging radionuclide, wherein the bifunctional chelating agent is selected from one or more of the following: DOTA, DOTAGA, NOTA, NOTAGA, NODA, DTPA, TETA, CB-TE2A, Cyclam, DFO, MAG3, EC, EDTA, DADT, HYNIC, CE-DTS, NS3, and is used for chelating the magnetic resonance imaging substance or the radionuclide.

[0021] According to the whole-process targeting molecule of the first aspect or the drug complex of the second aspect of the present invention, wherein in the whole-process targeting molecule-Y complex, Y is selected from one or more of the following: anthracyclines, taxanes, camptothecins, vinca alkaloids, proteasome inhibitors, anti-tumor stem cell drugs, molecular targeted drugs, polypeptide drugs, antibody drugs, and therapeutic radionuclide chelates in tumor chemotherapy drugs;

[0022] Preferably, the anthracycline drug in the tumor chemotherapy drug is selected from one or more of the following: doxorubicin, epirubicin;

[0023] Preferably, the taxane drugs are selected from one or more of the following: paclitaxel, docetaxel, cabazitaxel;

[0024] Preferably, the camptothecin drug is selected from one or more of the following: camptothecin, hydroxycamptothecin, 9-nitrocamptothecin, irinotecan;

[0025] Preferably, the vinca alkaloid drug is selected from one or more of the following: vinblastine, vincristine;

[0026] Preferably, the proteasome inhibitor drug is bortezomib;

[0027] Preferably, the anti-tumor stem cell drugs are selected from parthenolide and its derivatives;

[0028] Preferably, the molecular targeted drugs are selected from one or more of the following: trametinib, imatinib, nilotinib, dasatinib, everolimus, erlotinib, sunitinib, sorafenib, ibrutinib, regorafenib, vemurafenib, olaparib; and / or

[0029] Preferably, the polypeptide drug is selected from one or more of the following: p53 activating peptide, bee venom peptide, scorpion venom peptide, antimicrobial peptide;

[0030] Preferably, the antibody drug is selected from one or more of the following: rituximab, bevacizumab, trastuzumab, cetuximab, pertuzumab, ipilimumab, nivolumab, PD-L1 monoclonal antibody, and combinations of antibody fragments modified by genetic engineering including Fab fragments, single domain antibodies, Fv fragments, single chain antibodies, bivalent small molecule antibodies, mini antibodies, nano antibodies; and / or

[0031] Preferably, the therapeutic radionuclide chelate is selected from one or more of the following: 90 Y. 131 I. 152 / 155 Tb, 153 Sm, 177 Lu, 186 / 188 Re, 211 At 212 / 213 Bi, 212 Pb, 225 Ac, 227 Th therapeutic radionuclide chelates;

[0032] More preferably, the therapeutic radionuclide chelate consists of a bifunctional chelator and a therapeutic radionuclide, wherein the bifunctional chelator is selected from DOTA, DOTAGA, NOTA, NOTAGA, NODA, DTPA, TETA, CB-TE2A, Cyclam, DFO, MAG3, EC, EDTA, DADT, HYNIC, CE-DTS, and NS3.

[0033] The third aspect of the present invention provides a targeting functional carrier material, which is composed of the whole-process targeting molecule and a polymer carrier material as described in the first aspect, and can be used to prepare a nano drug delivery system with the whole-process targeting molecule modified on the surface;

[0034] Preferably, active functional groups are introduced into the full-process targeting molecule to construct a polymer carrier material complex modified by it; wherein, a polyethylene glycol-Z complex molecule is introduced into the full-process targeting molecule to obtain a targeting functional carrier material full-process targeting molecule-polyethylene glycol-Z complex, wherein Z is a lipophilic material molecule or a lipophilic drug molecule or a hydrophilic ligand molecule.

[0035] According to the whole process targeting molecule of the first aspect or the targeting functional carrier material of the third aspect of the present invention, the lipophilic material molecule Z is selected from one or more of the following: phospholipids, polylactic acid (PLA), lactic acid-glycolic acid copolymer (PLGA), polycaprolactone (PCL);

[0036] The lipophilic drug molecule Z is selected from one or more of the following: anthracyclines, taxanes, camptothecins, vinca alkaloids, proteasome inhibitors, lactone anti-tumor drugs; and / or

[0037] The hydrophilic ligand molecule Z is biotin.

[0038] The targeting functional carrier material can be further prepared into a nano drug delivery system with the whole process of targeting molecules modified on the surface.

[0039] The fourth aspect of the present invention provides the use of the whole-process targeting molecule of the first aspect or the targeting functional carrier material of the third aspect in the preparation of a nano drug delivery system, wherein when Z in the polyethylene glycol-Z complex introduced into the whole-process targeting molecule is a lipophilic material molecule phospholipid, the targeting functional carrier material is used to prepare a liposome drug delivery system, a micelle drug delivery system or a disc drug delivery system;

[0040] When Z in the polyethylene glycol-Z complex introduced into the whole process targeting molecule is a lipophilic material molecule polylactic acid complex, lactic acid glycolic acid copolymer and / or polycaprolactone, the targeting functional carrier material is used to prepare a micelle drug delivery system or a nanoparticle drug delivery system; and / or

[0041] When Z in the polyethylene glycol-Z complex introduced into the whole-process targeting molecule is a hydrophilic material molecule biotin, the targeting functional carrier material can be used to prepare a biomembrane-coated nano drug delivery system.

[0042] According to the fourth aspect of the present invention, the liposome drug delivery system, micelle drug delivery system, disc drug delivery system, nanoparticle drug delivery system and biofilm-coated nano drug delivery system are used to carry diagnostic drugs for imaging diagnosis and tracing of brain tumors or peripheral tumors;

[0043] Preferably, the diagnostic drug is selected from one or more of the following: optical imaging substances, magnetic resonance imaging agents, radionuclide imaging agents;

[0044] More preferably, the optical imaging substance is selected from one or more of the following: fluorescent probes coumarin 6, FITC, FAM, DiI, Rhodamine B, Rhodamine 6G, 5-TAMRA, 6-TET, HEX, 6-JOE, near-infrared dyes Cy3, Cy3.5, Cy5, Cy5.5, Cy7, IR783, IR820, DiR, DiD, Alexa Fluor 680, BIDIPY630 / 650-X, BIDIPY650 / 665-X, BIDIPY665 / 676, TO-PRO-3, TO-PRO-5, chemiluminescent substances luminol, isoluminol, AMPPD, CSPD, CDP-star, lucigenin, Raman probes;

[0045] More preferably, the magnetic resonance imaging agent is a chelate of a magnetic resonance imaging substance such as Gd; and / or

[0046] More preferably, the radionuclide imaging agent is selected from one or more of the following: 18 F. 32 P. 35 S. 64 Cu, 67 / 68 Ga, 75 Se, 89 Zr, 86 Y. 99m Tc, 111 / 111m In, 123 / 125 I. 177 Lu, 149 / 161 Chelated radionuclides for Tb imaging.

[0047] According to the fourth aspect of the present invention, the liposome drug delivery system, micelle drug delivery system, disc drug delivery system, nanoparticle drug delivery system and biofilm-coated nano drug delivery system are used to encapsulate tumor therapeutic drugs for targeted treatment of brain tumors or peripheral tumors with brain metastasis characteristics;

[0048] Preferably, the tumor therapeutic drug is selected from one or more of the following: anthracyclines, taxanes, camptothecins, vinblastines, platinum drugs, proteasome inhibitors, anti-tumor stem cell drugs, molecular targeted drugs, polypeptide drugs, antibody drugs, and therapeutic radionuclide chelates in chemotherapy;

[0049] More preferably, the anthracycline in the chemotherapy is selected from one or more of the following: doxorubicin, epirubicin;

[0050] More preferably, the taxane is selected from one or more of the following: paclitaxel, docetaxel, cabazitaxel;

[0051] More preferably, the camptothecin drug is selected from one or more of the following: camptothecin, hydroxycamptothecin, 9-nitrocamptothecin, irinotecan;

[0052] More preferably, the vinca alkaloids are selected from one or more of the following: vinblastine, vincristine;

[0053] More preferably, the platinum drug is selected from one or more of the following: cisplatin, carboplatin, oxaliplatin, miplatin;

[0054] More preferably, the proteasome inhibitor drug is selected from one or more of the following: bortezomib, carfilzomib;

[0055] More preferably, the anti-tumor stem cell drugs are selected from one or more of the following: parthenolide and its derivatives;

[0056] More preferably, the molecular targeted drug is selected from one or more of the following: trametinib, imatinib, nilotinib, dasatinib, everolimus, erlotinib, sunitinib, sorafenib, ibrutinib, regorafenib, vemurafenib, olaparib;

[0057] More preferably, the polypeptide drug is selected from one or more of the following: p53 activating peptide, melittin, scorpion venom peptide and antimicrobial peptide;

[0058] More preferably, the antibody drug is selected from one or more of the following: rituximab, bevacizumab, trastuzumab, cetuximab, pertuzumab, ipilimumab, nivolumab, PD-L1 monoclonal antibody, and combinations of antibody fragments modified by genetic engineering means including Fab fragments, single domain antibodies, Fv fragments, single chain antibodies, bivalent small molecule antibodies, mini antibodies, nano antibodies; and / or

[0059] More preferably, the therapeutic radionuclide chelate is selected from one or more of the following: 90 Y. 131 I. 152 / 155 Tb, 153 Sm, 177 Lu, 186 / 188 Re, 211 At 212 / 213 Bi, 212 Pb, 225 Ac, 227 Chelated Th therapeutic radionuclides.

[0060] The fifth aspect of the present invention provides a nano drug delivery system, the nano drug delivery system comprises the whole process targeting molecule of the first aspect or the targeting functional carrier material of the third aspect, and the nano drug delivery system is constructed by introducing a polyethylene glycol-Z complex into the whole process targeting molecule, wherein Z is a lipophilic material molecule or a lipophilic drug molecule or a hydrophilic ligand molecule;

[0061] The lipophilic material molecule Z is selected from one or more of the following: phospholipids, polylactic acid (PLA), lactic acid-glycolic acid copolymer (PLGA), polycaprolactone (PCL);

[0062] The lipophilic drug molecule Z is selected from one or more of the following: anthracyclines, taxanes, camptothecins, vinca alkaloids, proteasome inhibitors, lactone anti-tumor drugs; and / or

[0063] The hydrophilic ligand molecule Z is biotin.

[0064] According to the nano drug delivery system of the fifth aspect of the present invention, when the lipophilic material molecule Z is a phospholipid, the nano drug delivery system is a liposome drug delivery system, a micelle drug delivery system or a disc drug delivery system;

[0065] When the lipophilic material molecule Z is polylactic acid, lactic acid-co-glycolic acid copolymer and / or polycaprolactone, the nano drug delivery system is a micelle drug delivery system or a nanoparticle drug delivery system; and / or

[0066] When the hydrophilic ligand molecule Z is biotin, the nano drug delivery system is a biomembrane-coated nano drug delivery system.

[0067] According to the fifth aspect of the present invention, the nano drug delivery system, wherein the liposome drug delivery system, micelle drug delivery system, disc drug delivery system, nanoparticle drug delivery system and biofilm-coated nano drug delivery system encapsulate diagnostic drugs for imaging diagnosis and tracing of brain tumors or peripheral tumors;

[0068] Preferably, the diagnostic drug is selected from one or more of the following: optical imaging substances, magnetic resonance imaging agents, radionuclide imaging agents;

[0069] More preferably, the optical imaging substance is selected from one or more of the following: fluorescent probes coumarin 6, FITC, FAM, DiI, Rhodamine B, Rhodamine 6G, 5-TAMRA, 6-TET, HEX, 6-JOE, near-infrared dyes Cy3, Cy3.5, Cy5, Cy5.5, Cy7, IR783, IR820, DiR, DiD, Alexa Fluor 680, BIDIPY630 / 650-X, BIDIPY650 / 665-X, BIDIPY665 / 676, TO-PRO-3, TO-PRO-5, chemiluminescent substances luminol, isoluminol, AMPPD, CSPD, CDP-star, lucigenin, Raman probes;

[0070] More preferably, the magnetic resonance imaging agent is a chelate of a magnetic resonance imaging substance such as Gd; and / or

[0071] More preferably, the radionuclide imaging agent is selected from one or more of the following: 18 F. 32 P. 35 S. 64 Cu, 67 / 68 Ga, 75 Se, 89 Zr, 86 Y. 99m Tc, 111 / 111m In, 123 / 125 I. 177 Lu, 149 / 161 Chelated radionuclides for Tb imaging.

[0072] According to the fifth aspect of the present invention, the nano drug delivery system, wherein the liposome drug delivery system, micelle drug delivery system, disc drug delivery system, nanoparticle drug delivery system and biofilm-coated nano drug delivery system encapsulate tumor therapeutic drugs for targeted treatment of brain tumors or peripheral tumors with brain metastasis characteristics;

[0073] Preferably, the tumor therapeutic drug is selected from one or more of the following: anthracyclines, taxanes, camptothecins, vinblastines, platinum drugs, proteasome inhibitors, anti-tumor stem cell drugs, molecular targeted drugs, polypeptide drugs, antibody drugs, and therapeutic radionuclide chelates in chemotherapy;

[0074] More preferably, the anthracycline in the chemotherapy is selected from one or more of the following: doxorubicin, epirubicin;

[0075] More preferably, the taxane is selected from one or more of the following: paclitaxel, docetaxel, cabazitaxel;

[0076] More preferably, the camptothecin drug is selected from one or more of the following: camptothecin, hydroxycamptothecin, 9-nitrocamptothecin, irinotecan;

[0077] More preferably, the vinca alkaloids are selected from one or more of the following: vinblastine, vincristine;

[0078] More preferably, the platinum drug is selected from one or more of the following: cisplatin, carboplatin, oxaliplatin, miplatin;

[0079] More preferably, the proteasome inhibitor drug is selected from one or more of the following: bortezomib, carfilzomib;

[0080] More preferably, the anti-tumor stem cell drugs are selected from one or more of the following: parthenolide and its derivatives;

[0081] More preferably, the molecular targeted drug is selected from one or more of the following: trametinib, imatinib, nilotinib, dasatinib, everolimus, erlotinib, sunitinib, sorafenib, ibrutinib, regorafenib, vemurafenib, olaparib;

[0082] More preferably, the polypeptide drug is selected from one or more of the following: p53 activating peptide, melittin, scorpion venom peptide and antimicrobial peptide;

[0083] More preferably, the antibody drug is selected from one or more of the following: rituximab, bevacizumab, trastuzumab, cetuximab, pertuzumab, ipilimumab, nivolumab, PD-L1 monoclonal antibody, and combinations of antibody fragments modified by genetic engineering means including Fab fragments, single domain antibodies, Fv fragments, single chain antibodies, bivalent small molecule antibodies, mini antibodies, nano antibodies; and / or

[0084] More preferably, the therapeutic radionuclide chelate is selected from one or more of the following: 90 Y. 131 I. 152 / 155 Tb, 153 Sm, 177 Lu, 186 / 188 Re, 211 At 212 / 213 Bi, 212 Pb, 225 Ac, 227 Chelated Th therapeutic radionuclides.

[0085] The sixth aspect of the present invention provides a method for diagnosing and / or treating a brain tumor or a peripheral tumor with brain metastasis characteristics, the method comprising: administering the whole-process targeting molecule of the first aspect, the drug complex of the second aspect, or the targeting functional carrier material of the third aspect, or the nano drug delivery system of the fifth aspect to a subject in need;

[0086] Preferably, the method is achieved by targeting brain capillary endothelial cells and crossing the blood-brain barrier, targeting tumor neovascular endothelial cells and crossing the blood-tumor barrier, and simultaneously targeting tumor mimetic blood vessels, tumor cells and tumor stem cells through the whole-process targeting molecule, drug complex, targeted functional carrier material or nano drug delivery system;

[0087] More preferably, the method is to achieve targeted delivery of imaging molecules, therapeutic drugs and nano-drug delivery systems to brain tumors and peripheral tumors with brain metastasis characteristics by crossing the blood-brain barrier and the blood-tumor barrier, targeting tumor-mimicking blood vessels, tumor cells and / or tumor stem cells through the whole process targeting molecules, drug complexes, targeted functional carrier materials or nano-drug delivery systems.

[0088] Specifically, the present invention utilizes the principle of molecular fusion to covalently link brain-targeting molecules and tumor-targeting molecules to prepare a full-process targeting molecule, which has the targeting capabilities of both molecules at the same time, and can target brain capillary endothelial cells (across the BBB), tumor neovascular endothelial cells (across the BTB), tumor mimicking blood vessels, tumor cells and tumor stem cells, and has a targeting effect on the entire process of brain tumor growth and development.

[0089] The targeting molecules such as small molecules, polypeptide molecules or protein molecules that cross the blood-brain barrier involved in the present invention include: p-hydroxybenzoic acid (pHA) and its derivatives, fatty acids, especially myristic acid (MC) and its derivatives, D8 polypeptide, WSW polypeptide, D WSW peptide, TGN peptide, D TGN peptide, CDX peptide, D CDX peptide, T7 peptide and D T7 polypeptide and other polypeptides and their derivatives, transferrin, lactoferrin and other proteins and their derivatives. The polypeptide sequences are shown in Table 1 of the specification (Table 1 - polypeptide amino acid sequence table).

[0090] The targeting molecules such as polypeptide molecules or protein molecules that cross the blood-tumor barrier involved in the present invention include: VAP polypeptide, cVAP polypeptide, S VAP peptide, D VAP polypeptide, A7R polypeptide, cA7R polypeptide, D A7R polypeptide, RGD polypeptide, Stapled-RGD polypeptide, RW polypeptide, mn polypeptide, RAP12 polypeptide and D RAP12 polypeptide and other polypeptides and their derivatives. The polypeptide sequences are shown in Table 1 of the specification (Table 1 - polypeptide amino acid sequence table).

[0091] Table 1 - Amino acid sequence list of polypeptide targeting molecules

[0092]

[0093]

[0094] The whole-process targeting molecule designed by the present invention can construct its modified imaging molecule complex, therapeutic drug complex, and targeting functional carrier material by introducing active functional groups into the molecule.

[0095] After cysteine ​​is introduced into the whole-process targeting molecule designed by the present invention, the thiol group in the molecule is used to react with maleimide-functionalized optical imaging molecules (such as fluorescent probe molecules FITC, FAM, 6-TET, 5-TAMRA, HEX, 6-JOE, etc., near-infrared dyes such as Cy3, Cy3.5, Cy5, Cy5.5, Cy7, IR783, IR820, DiR, DiD, BIDIPY630 / 650-X, BIDIPY650 / 665-X, BIDIPY665 / 676, TO-PRO-3, TO-PRO-5, etc., chemiluminescent molecules luminol, isoluminol, AMPPD, CSPD, CDP-star, lucigenin, etc., Raman probe molecules, etc.) to form a complex.

[0096] The whole process targeting molecule designed by the present invention is combined with a magnetic resonance imaging agent (such as a chelate of a magnetic resonance imaging substance such as Gd) or a radionuclide imaging agent (such as 18 F. 32 P. 35 S. 64 Cu, 67 / 68 Ga, 75 Se, 89 Zr, 86 Y. 99m Tc, 111 / 111m In, 123 / 125 I. 177 Lu, 149 / 161 Tb and other imaging radionuclides), or chelates with therapeutic radionuclides (such as 90 Y. 131 I. 152 / 155 Tb, 153 Sm, 177 Lu, 186 / 188 Re, 211 At 212 / 213 Bi, 212 Pb, 225 Ac, 227The invention relates to a chelate of a therapeutic radionuclide such as Th to form a complex, wherein the chelate is composed of a bifunctional chelator and a radionuclide for magnetic resonance imaging, or a bifunctional chelator and a radionuclide for imaging, or a bifunctional chelator and a radionuclide for therapeutic use. The bifunctional chelator in the chelate includes DOTA, DOTAGA, NOTA, NOTAGA, NODA, DTPA, TETA, CB-TE2A, Cyclam, DFO, MAG3, EC, EDTA, DADT, HYNIC, CE-DTS, NS3, etc.

[0097] The whole process targeted molecular modification drug designed by the present invention includes forming a pH-sensitive hydrazone bond through the reaction of maleimide hexahydrazine derivatives (involving drugs containing ketone or aldehyde groups such as doxorubicin and epirubicin), or forming a disulfide bond through the reaction of 3-(2-pyridinedithiol) propionic acid derivatives (involving drugs containing hydroxyl or amino groups such as paclitaxel, docetaxel, cabazitaxel, camptothecin, hydroxycamptothecin, 9-nitrocamptothecin, irinotecan, vincristine and vinorelbine), or forming a pH-sensitive boric acid ester through the reaction of dopamine with the boric acid group in the drug (involving drugs containing boric acid groups such as bortezomib). Drugs), or directly forming amide bonds through solid phase synthesis (involving polypeptide drugs such as p53 activating peptides, bee venom peptides, scorpion venom peptides and antimicrobial peptides), or through covalent or non-covalent linkage (involving antibody drugs such as rituximab, bevacizumab, trastuzumab, cetuximab, pertuzumab, ipilimumab, nivolumab, PD-L1 monoclonal antibodies and antibody fragment combinations modified by genetic engineering, including Fab fragments, single domain antibodies, Fv fragments, single chain antibodies, bivalent small molecule antibodies, mini antibodies, nano antibodies, etc.) to synthesize the whole process of targeted molecule-drug complexes.

[0098] After cysteine ​​is introduced into the whole-process targeting molecule designed by the present invention, it is modified on a polymer carrier material such as polyethylene glycol-distearoylphosphatidylethanolamine (PEG-DSPE), polyethylene glycol-polylactic acid (PEG-PLA), polyethylene glycol-lactic acid copolymer (PEG-PLGA), polyethylene glycol-polycaprolactone (PEG-PCL) containing a maleimide functional group, and is used for the construction of nano drug delivery systems such as liposomes, micelles, discs, nanoparticles, etc. modified with the whole-process targeting molecule.

[0099] The whole-process targeting molecule designed by the present invention is modified on a targeting material such as polyethylene glycol-biotin (PEG-Biotin) containing a maleimide functional group after introducing cysteine, and is used for the construction of a biofilm-coated nano-drug delivery system modified with the whole-process targeting molecule.

[0100] The whole-process targeted molecular modified nano drug delivery system designed by the present invention is used to encapsulate anthracycline drugs such as doxorubicin and epirubicin, taxane drugs such as paclitaxel, docetaxel, cabazitaxel, camptothecin drugs such as camptothecin, hydroxycamptothecin, 9-nitrocamptothecin, irinotecan, vinblastine drugs such as vincristine and vinorelbine, platinum drugs such as cisplatin, carboplatin, oxaliplatin, miplatin, proteasome inhibitors such as bortezomib and carfilzomib, lactone drugs such as parthenolide, trametinib, imatinib, nilotinib, dasatinib, etc. Molecular targeted drugs such as nivolumab, everolimus, erlotinib, sunitinib, sorafenib, ibrutinib, regorafenib, vemurafenib, olaparib, etc., peptide drugs such as p53 activation peptide, bee venom peptide, scorpion venom peptide, antimicrobial peptide, etc., antibody drugs such as rituximab, bevacizumab, trastuzumab, cetuximab, pertuzumab, ipilimumab, nivolumab, PD-L1 monoclonal antibody, and antibody fragment combinations modified by genetic engineering (including Fab fragments, single domain antibodies, Fv fragments, single chain antibodies, bivalent small molecule antibodies, mini antibodies and nano antibodies, etc.), 90 Y. 131 I. 152 / 155 Tb, 153 Sm, 177 Lu, 186 / 188 Re, 211 At 212 / 213 Bi, 212 Pb, 225 Ac, 227 Chelates of therapeutic radionuclides such as Th.

[0101] The whole-process targeted molecule-modified nano drug delivery system designed by the present invention is used to encapsulate optical imaging molecules (such as fluorescent probe molecules FITC, FAM, 6-TET, 5-TAMRA, HEX, 6-JOE, etc., near-infrared dyes Cy3, Cy3.5, Cy5, Cy5.5, Cy7, IR783, IR820, DiR, DiD, BIDIPY630 / 650-X, BIDIPY650 / 665-X, BIDIPY665 / 676, TO-PRO-3, TO-PRO-5, etc., chemiluminescent substances luminol, isoluminol, AMPPD, CSPD, CDP-star, lucigenin, etc., Raman probe molecules), encapsulate magnetic resonance imaging agents (such as chelates of magnetic resonance substances such as Gd), encapsulate radionuclide imaging agents (such as 18 F. 32 P. 35 S. 64 Cu, 67 / 68 Ga, 75 Se, 89 Zr,86 Y. 99m Tc, 111 / 111m In, 123 / 125 I. 177 Lu, 149 / 161 Chelates of radionuclides for imaging such as Tb).

[0102] The whole-process targeting molecule designed by the present invention is used to mediate drugs or nano-drug delivery systems across the BBB and BTB, targeting tumor neovascularization, tumor mimicry vessels, tumor cells and tumor stem cells, and is used for targeted diagnosis and treatment of the brain, brain tumors or peripheral tumors with brain metastasis characteristics.

[0103] 1. Preparation of pHA-VAP and its fluorescent marker (pHA-VAP-Cy7)

[0104] pHA-VAP was prepared by solid phase synthesis. pHA-VAP-Cy7 was synthesized by Michael addition reaction of maleimide group and thiol group. Its structure was characterized by HPLC and MS.

[0105] 2. Preparation of pHA-VAP-imaging agent

[0106] pHA-VAP-DTPA or pHA-VAP-DOTA was synthesized by Michael addition reaction of maleimide group with thiol group to chelate Gd or 99m Tc to pHA-VAP-DTPA-Gd or pHA-VAP-DTPA- 99m Tc, or pHA-VAP-DOTA-Gd.

[0107] 3. Evaluation of pHA-VAP targeting ability in vivo and in vitro

[0108] The in vitro affinity of pHA-VAP-Cy7 to brain capillary endothelial cells (BCEC), umbilical vein endothelial cells (HUVEC) and model tumor cells (such as brain glioma cells U87) was investigated. The uptake of pHA-VAP-DOTA-Gd by model tumor cells (HCC1806 and A549 cells) was investigated.

[0109] pHA-VAP-Cy7 was injected into the tail vein of normal mice and nude mice bearing U87 subcutaneous transplanted tumors and U87 intracranial orthotopic tumor models, and its distribution in the animals at different time points was investigated.

[0110] 4. Preparation of pHA-VAP-drug complex

[0111] After the introduction of cysteine, pHA-VAP reacts with maleimide hexahydrazine derivatives on the drug to form a peptide-drug complex containing a pH-sensitive hydrazone bond, wherein the drugs involved include doxorubicin, epirubicin and other drugs containing ketone or aldehyde groups.

[0112] After the introduction of cysteine, pHA-VAP reacts with 3-(2-pyridyldithiol)propionic acid derivatives on the drug to form a disulfide bond-containing polypeptide-drug complex, wherein the drugs involved include paclitaxel, docetaxel, cabazitaxel, camptothecin, hydroxycamptothecin, 9-nitrocamptothecin, irinotecan, vincristine, vinorelbine and other drugs containing hydroxyl or amino groups.

[0113] pHA-VAP modifies dopamine and then reacts with the boronic acid group on the drug to form a peptide-drug complex containing pH-sensitive boronic acid lipids. The drugs involved include boronic acid group-containing drugs such as bortezomib.

[0114] pHA-VAP is directly condensed with peptide drugs through solid phase synthesis, and the drugs involved include p53 activation peptides, antimicrobial peptides, peptide toxins and other peptide drugs.

[0115] pHA-VAP is modified by random sites (activating free amino groups in the antibody and then covalently linking them to pHA-VAP) or fixed sites (non-covalently linking the targeting molecule to the antibody through affinity coupling) to obtain an antibody complex modified with a targeting functional molecule. The drugs involved include antibody drugs such as rituximab, bevacizumab, trastuzumab, cetuximab, pertuzumab, ipilimumab, nivolumab, PD-L1 monoclonal antibody, and antibody fragment combinations modified by genetic engineering (including Fab fragments, single domain antibodies, Fv fragments, single chain antibodies, bivalent small molecule antibodies, mini antibodies, nano antibodies, etc.).

[0116] 5. Evaluation of the anti-tumor effect of pHA-VAP-doxorubicin complex in vivo and in vitro

[0117] The pHA-VAP-doxorubicin complex (pHA-VAP-DOX) was obtained by condensing pHA-VAP after linking cysteine ​​with the maleimidohydrazine derivative (MAL-DOX) on doxorubicin. The in vitro growth inhibitory effect of pHA-VAP-DOX on U87 cells and HUVEC cells was investigated by MTT method; the drug was administered through the tail vein of nude mice bearing U87 intracranial orthotopic tumor model, and its in vivo anti-tumor effect was evaluated by median survival time.

[0118] 6. Construction and characterization of pHA-VAP modified nanodrug delivery system

[0119] First, pHA-VAP modified polymer materials pHA-VAP-PEG-DSPE, pHA-VAP-PEG-PLA, pHA-VAP-PEG-PLGA, pHA-VAP-PEG-PCL, pHA-VAP-PEG-biotin, etc. are prepared. Cysteine ​​is introduced into pHA-VAP, and its free thiol reacts with maleimide contained in Mal-PEG-DSPE, Mal-PEG-PLA, Mal-PEG-PLGA, Mal-PEG-PCL, Mal-PEG-biotin, etc. to achieve the preparation of the above-mentioned targeted polymer materials, that is, Mal-PEG-DSPE, Mal-PEG-PLA, Mal-PEG-PLGA, Mal-PEG-PCL, Mal-PEG-biotin, etc. are dissolved in acetonitrile, rotary evaporated, film formed, and PBS (pH 8.0) containing thiol pHA-VAP is added to react to prepare the pHA-VAP modified polymer material.

[0120] Then, a pHA-VAP modified nano drug delivery system was constructed. A certain amount of pHA-VAP-PEG-DSPE, mPEG-DSPE, phospholipids and cholesterol, or pHA-VAP-PEG-DSPE and mPEG-DSPE, or pHA-VAP-PEG-PLA and mPEG-PLA, or pHA-VAP-PEG-PLGA and mPEG-PLGA, or pHA-VAP-PEG-PCL and mPEG-PCL, and a certain amount of the above drugs were used to construct the corresponding pHA-VAP modified liposomes, micelles, discs, nanoparticles and other nano drug delivery systems by film-forming hydration and other methods; after a certain amount of pHA-VAP-PEG-biotin and pre-modified avidin biofilm were incubated, the polymer nanoparticles, silicon nanoparticles, nanogels, nanocrystals and other nano drug delivery systems loaded with the above drugs were coated to construct a biofilm coated nano drug delivery system. The particle size and potential of the nano drug delivery system were characterized by a laser scattering particle size meter, and its morphological characteristics were characterized by transmission electron microscopy.

[0121] 7. Evaluation of the targeting ability of pHA-VAP modified nanodrug delivery system in vivo and in vitro

[0122] The uptake of pHA-VAP modified nanodrug delivery system encapsulating tumor therapeutic drugs by BCEC cells, tumor cells (U87 cells, 4T1 cells) and HUVEC cells was investigated.

[0123] The pHA-VAP modified nanodrug delivery system loaded with tumor therapeutic drugs was injected into the tail vein of nude mice bearing U87 intracranial orthotopic tumor model or balb / c mice bearing 4T1 breast cancer orthotopic model, and its distribution in the tumor at different time points was investigated.

[0124] 8. Evaluation of the anti-tumor effect of pHA-VAP modified nano-drug delivery system in vivo and in vitro

[0125] The MTT method was used to investigate the in vitro growth inhibitory effect of the pHA-VAP modified nanodrug delivery system loaded with tumor therapeutic drugs on tumor cells (U87 cells, 4T1 cells) and HUVEC cells. The pHA-VAP modified nanodrug delivery system loaded with tumor therapeutic drugs was injected into the tail vein of nude mice bearing the U87 intracranial orthotopic tumor model or balb / c mice bearing the 4T1 breast cancer orthotopic model, and its in vivo anti-tumor effect was evaluated using the survival time, tumor inhibition curve, tumor tissue cell apoptosis, new blood vessels and stem cell number as indicators.

[0126] The method provided by the present invention is used to design and prepare the whole-process targeting molecule pHA-VAP and its modified drug complex and nano drug delivery system. The test results of the present invention show that pHA-VAP has the ability of pHA targeting brain capillaries and crossing the BBB, VAP targeting tumor neovascular endothelial cells and crossing the BTB, targeting tumor mimic blood vessels, tumor cells and tumor stem cells, and has good brain and tumor tissue targeting ability in model animals and shows better brain tumor targeting effect; pHA-VAP modified drug complex and nano drug delivery system show good tumor targeting performance and better brain tumor diagnosis and treatment effect.

[0127] BRIEF DESCRIPTION OF THE DRAWINGS

[0128] The embodiments of the present invention are described in detail below with reference to the accompanying drawings, wherein:

[0129] Figure 1 HPLC and ESI-MS spectra of pHA-VAP-Cys are shown

[0130] Chromatographic method: Chromatographic column (YMC, C18): 150×4.6mm; Mobile phase A: water (containing 0.1% trifluoroacetic acid), mobile phase B: acetonitrile (containing 0.1% trifluoroacetic acid); Elution program: 0-45min 5%B-65%B; Flow rate: 0.7mL / min; Column temperature: 40℃; Detection: UV 214nm, retention time: 16min. ESI-MS: 1080.4, consistent with the theoretical molecular weight. Figure 1 A shows the ESI-MS spectrum, Figure 1 B shows the HPLC spectrum.

[0131] Figure 2 HPLC and ESI-MS spectra of pHA-VAP-Cy7 are shown

[0132] The chromatographic method is the same as above, retention time: 25min. ESI-MS: 1750.6, consistent with the theoretical molecular weight. Figure 2 A shows the ESI-MS spectrum, Figure 2 B shows the HPLC spectrum.

[0133] Figure 3 HPLC and ESI-MS spectra of pHA-VAP-DOTA-Gd are shown

[0134] The chromatographic method was the same as above except that trifluoroacetic acid was not included in the mobile phase. Retention time: 21 min. ESI-MS: 1831.8, consistent with the theoretical molecular weight.

[0135] Figure 4 Figure 2 shows the uptake of Cy7-labeled pHA-VAP by primary brain capillary endothelial cells (BCEC)

[0136] The figure shows the quantitative analysis of flow cytometry fluorescence after Cy7-labeled VAP and pHA-VAP were incubated with BCEC cells for 4 hours ( Figure 4 A) and qualitative ( Figure 4 B) Results: It can be seen that the uptake of pHA-VAP by BCEC cells was significantly higher than that of VAP and free fluorescein.

[0137] Figure 5 Figure 2 shows the uptake of Cy7-labeled pHA-VAP by umbilical vein endothelial cells (HUVEC)

[0138] The figure shows the quantitative analysis of flow cytometry fluorescence after Cy7-labeled VAP and pHA-VAP were incubated with HUVEC cells for 4 hours ( Figure 5 A) and qualitative ( Figure 5 B) Results: It can be seen that the uptake of pHA-VAP by U87 cells was significantly higher than that of VAP and free fluorescein.

[0139] Figure 6 Figure 2 shows the uptake of Cy7-labeled pHA-VAP by U87 glioma cells.

[0140] The figure shows the quantitative analysis of flow cytometry fluorescence after Cy7-labeled VAP and pHA-VAP were incubated with U87 cells for 4 hours ( Figure 6 A) and qualitative ( Figure 6 B) Results: It can be seen that the uptake of pHA-VAP by U87 cells was significantly higher than that of VAP and free fluorescein.

[0141] Figure 7 Figure 2 shows the uptake of pHA-VAP-DOTA-Gd by tumor cells HCC1806 or A549.

[0142] The figure shows the intracellular Gd uptake measured by ICP-MS after pHA-VAP-DOTA-Gd and DOTA-Gd were incubated with HCC1806 or A549 cells for 4 hours. It can be seen that the uptake of pHA-VAP-DOTA-Gd by HCC1806 and A549 cells was significantly higher than that of the unmodified group.

[0143] Figure 8 The tissue distribution of Cy7-labeled pHA-VAP in mice bearing U87 subcutaneous tumor model is shown.

[0144] As can be seen from the figure, compared with free fluorescein and VAP-Cy7, the distribution of pHA-VAP-Cy7 in subcutaneous tumors increased within 4 hours, and the accumulation decreased after 24 hours.

[0145] Fig. 9 The tissue distribution of Cy7-labeled pHA-VAP in mice bearing the U87 brain orthotopic tumor model is shown.

[0146] As can be seen from the figure, compared with free fluorescein and VAP-Cy7, the distribution of pHA-VAP-Cy7 in the in situ tumor increased within 24 hours, indicating that the targeting molecule can cross the blood-brain barrier and blood-brain tumor barrier and significantly increase the accumulation of the drug in the brain tumor site.

[0147] Fig.10 HPLC and ESI-MS spectra of pHA-VAP-DOX are shown

[0148] Chromatographic method: Chromatographic column (YMC, C18): 150×4.6mm; Mobile phase A: water (containing 0.01% formic acid), Mobile phase B: pure acetonitrile; Elution program: 0-45min 5%B-65%B; Flow rate: 0.7mL / min; Column temperature: 40℃; Detection: UV 214nm, Retention time: 17min. ESI-MS: 1832.2, consistent with the theoretical molecular weight. Fig.10 A shows the ESI-MS spectrum, Fig.10 B shows the HPLC spectrum.

[0149] Fig.11 The in vitro anti-U87 cell activity curve of pHA-VAP-DOX is shown.

[0150] As can be seen from the figure, after U87 cells were incubated with DOX, MAL-DOX, VAP-DOX or pHA-VAP-DOX for 72 h, their IC 50 The results showed that pHA-VAP modified doxorubicin had better antitumor activity in vitro than maleamide doxorubicin and VAP modified doxorubicin.

[0151] Fig.12 The in vitro anti-HUVEC cell activity curve of pHA-VAP-DOX is shown

[0152] As can be seen from the figure, after HUVEC cells were incubated with DOX, MAL-DOX, VAP-DOX or pHA-VAP-DOX for 72 h, their IC 50 The values ​​were 0.20, 1.50, 0.70 and 0.30 μM respectively. The results showed that the antitumor activity of pHA-VAP modified doxorubicin in vitro was better than that of maleamide doxorubicin and VAP modified doxorubicin.

[0153] Fig.13 The survival curve of pHA-VAP-DOX against U87 orthotopic glioma is shown

[0154] The figure shows the survival curve of nude mice with U87 orthotopic glioma model. Taking the median survival time of model animals as an indicator, compared with normal saline (median survival time 26 days), DOX (10mg, 20mg, 40mg median survival time 27, 17, 13 days, medium and high doses of doxorubicin are highly toxic and lead to shorter survival of model nude mice), pHA-VAP (median survival time 28 days), pHA-VAP-DOX (10mg, 20mg, 40mg median survival time 29, 32, 40 days, respectively) prolonged the survival time of model animals, and there was dose dependence.

[0155] Fig.14 Electron microscopic image of the nano-drug delivery system of cabazitaxel nanocrystals coated with pHA-VAP modified lipid membrane

[0156] As can be seen from the figure, Cabazitaxel Nanocrystals ( Fig.14 A) Spherical, with a particle size of about 80 nm; pHA-VAP modified lipid membrane coated cabazitaxel nanocrystals ( Fig.14 B. Fig.14 C) It is spherical, has a distinct core-membrane structure, and has a particle size of about 100 nm.

[0157] Fig.15 Figure 2 shows the particle size characterization of the nano drug delivery system of pHA-VAP modified erythrocyte membrane coated with docetaxel / parthenolide nano co-crystals

[0158] As can be seen from the figure, the particle size of docetaxel / parthenolide nano-cocrystal is about 130nm, and the potential is -20mV; after being coated with red blood cell membrane, the particle size is about 140nm, and the potential is -25mV; pHA-VAP modification has no obvious effect on the particle size of the constructed nano-drug delivery system, but because the molecule itself is positively charged, the potential of the modified nano-drug delivery system rises to -15mV.

[0159] Fig.16The uptake of pHA-VAP modified lipid membrane coated cabazitaxel nanocrystals by umbilical vein endothelial cells HUVEC and breast cancer cells 4T1 is shown

[0160] As can be seen from the figure, HUVEC cells ( Fig.16 A) and 4T1 cells ( Fig.16 B) The uptake of pHA-VAP modified lipid membrane coated cabazitaxel nanocrystals was significantly higher than that of the free drug group, nanocrystal group and non-target lipid membrane coated cabazitaxel nanocrystal group.

[0161] Fig.17 The uptake of pHA-VAP modified erythrocyte membrane coated docetaxel / parthenolide nano-cocrystals by primary brain capillary endothelial cells BCEC, umbilical vein endothelial cells HUVEC and brain glioma cells U87 is shown.

[0162] As can be seen from the figure, BCEC cells ( Fig.17 A, Fig.17 B) HUVEC cells ( Fig.17 C, Fig.17 D) and U87 cells ( Fig.17 E, Fig.17 F) The uptake of pHA-VAP modified erythrocyte membrane-coated drug nano-eutectics (docetaxel and parthenolide) was significantly higher than that of the nano-eutectic group and the non-target erythrocyte membrane-coated drug nano-eutectic group, and was equivalent to that of the free drug group.

[0163] Fig.18 The tissue distribution of pHA-VAP modified lipid membrane coated cabazitaxel nanocrystals in mice bearing 4T1 breast cancer orthotopic tumor model is shown.

[0164] As can be seen from the figure, pHA-VAP modification can significantly increase the accumulation of lipid membrane-coated cabazitaxel nanocrystals in the 4T1 tumor site at different time points, and better target the tumor site.

[0165] Fig.19 The tissue distribution of pHA-VAP modified erythrocyte membrane coated docetaxel / parthenolide nano-cocrystal in the U87 orthotopic glioma model mice is shown.

[0166] As shown in the figure, pHA-VAP modification can significantly increase the red blood cell membrane-coated drug nano-cocrystals (docetaxel ( Fig.19 A) and parthenolide ( Fig.19 B)) Accumulation in the brain glioma site, better targeting to the tumor site.

[0167] Fig. 20 The in vitro anti-HUVEC and 4T1 cell activity curves of pHA-VAP modified lipid membrane coated cabazitaxel nanocrystals are shown

[0168] As can be seen from the figure, after the two cells were incubated with free cabazitaxel, cabazitaxel nanocrystals, lipid membrane-coated cabazitaxel nanocrystals, and pHA-VAP-modified lipid membrane-coated cabazitaxel nanocrystals for 48 hours, their IC 50 0.88, 8.51, 2.93 and 0.06 nM respectively ( Fig. 20 A), IC of HUVEC cells 50 30.3, 1.86, 1.61 and 1.49 nM respectively ( Fig. 20 B). The results showed that the in vitro antitumor effect of pHA-VAP modified lipid membrane coated cabazitaxel nanocrystals was better than that of all groups.

[0169] Fig.21 The in vitro anti-HUVEC and U87 cell activity curves of pHA-VAP modified erythrocyte membrane coated docetaxel / parthenolide nano-cocrystals are shown.

[0170] As can be seen from the figure, the two cells were incubated with free docetaxel / parthenolide, docetaxel / parthenolide nanococrystals, erythrocyte membrane-coated docetaxel / parthenolide nanococrystals, and pHA-VAP-modified erythrocyte membrane-coated docetaxel / parthenolide nanococrystals for 48 hours, showing their IC 50 23.7, 44.6, 67.0 and 7.0 nM respectively ( Fig.21 A) For U87 IC 50 45.6, 79.9, 90.3 and 3.2 nM respectively ( Fig.21 B). The results showed that the in vitro antitumor effect of pHA-VAP modified erythrocyte membrane coated docetaxel / parthenolide nano-cocrystals was superior to that of all groups.

[0171] Fig. 22 The volume change curve of pHA-VAP modified lipid membrane coated cabazitaxel nanocrystals against 4T1 breast cancer in situ tumors is shown

[0172] The figure shows the curve of tumor volume change over time in each group of balb / c mice. Compared with the PBS group, each drug-treated group had an inhibitory effect on tumor growth. There was a significant difference between the non-target lipid membrane-coated cabazitaxel nanocrystals and pHA-VAP-modified cabazitaxel nanocrystals (n=6), and the pHA-VAP-modified lipid membrane-coated cabazitaxel nanocrystals had the best in vivo efficacy.

[0173] Fig.23 Comparative graph showing the anti-tumor effect of pHA-VAP modified lipid membrane coated cabazitaxel nanocrystals on 4T1 breast cancer in situ tumors

[0174] The balb / c mice were sacrificed and the tumor tissues were taken out and weighed for statistical analysis. The tumor weight of the pHA-VAP modified lipid membrane coated cabazitaxel nanocrystal group was significantly lower than that of the other groups (n=6).

[0175] Fig.24 The survival curve of pHA-VAP modified erythrocyte membrane coated docetaxel / parthenolide nano-cocrystal against U87 in situ brain glioma is shown

[0176] The figure shows the survival curve of nude mice with U87 orthotopic brain glioma in each group. A single tail vein administration was used, and the survival of the model animals was used as the evaluation index (n = 10). Compared with PBS (median survival time 38 days), free docetaxel / parthenolide (median survival time 40.5 days), and erythrocyte membrane-coated docetaxel / parthenolide nano-eutectic (median survival time 41.5 days), pHA-VAP-modified erythrocyte membrane-coated docetaxel / parthenolide nano-eutectic mice had a significantly prolonged survival time (median survival time 77 days) (***p < 0.001).

[0177] Fig.25 The results show the inhibitory effect of pHA-VAP modified lipid membrane coated cabazitaxel nanocrystals on apoptosis and angiogenesis of 4T1 breast cancer cells in situ

[0178] The figure shows the staining photos of two types of cells with free cabazitaxel, cabazitaxel nanocrystals, lipid membrane-coated cabazitaxel nanocrystals, and pHA-VAP-modified lipid membrane-coated cabazitaxel nanocrystals, respectively, which inhibit the neovascularization of 4T1 in situ tumors (upper figure) and promote tumor cell apoptosis (lower figure), in which the blood vessels (CD31 staining) are brown-red or brown, and the apoptotic cells (TUNEL staining) are green.

[0179] Fig.26 The effect of pHA-VAP modified erythrocyte membrane coated docetaxel / parthenolide nano-cocrystal on tumor cell apoptosis, angiogenesis inhibition and tumor stem cell killing in U87 in situ brain glioma is shown.

[0180] The picture shows the TUNEL staining (green) of apoptotic tumor cells, CD31 staining (red) of new blood vessels, and CD133 staining (red) of tumor stem cells in the U87 orthotopic tumor site, where blue is DAPI staining of cell nuclei. As can be seen from the figure, compared with the other three groups, pHA-VAP modified erythrocyte membrane coated with docetaxel / parthenolide nano-cocrystals can significantly promote tumor apoptosis, inhibit new blood vessel formation, and kill tumor stem cells.

[0181] Best Mode for Carrying Out the Invention

[0182] To further illustrate the technical means and effects of the present invention, the present invention is further described below in conjunction with the embodiments and drawings. It should be understood that the specific implementation methods described herein are only used to explain the present invention, rather than to limit the present invention.

[0183] If no specific techniques or conditions are specified in the examples, the techniques or conditions described in the literature in the field or the product instructions are used. If no manufacturer is specified for the reagents or instruments used, they are all conventional products that can be purchased through regular channels.

[0184] Example 1 Synthesis and Characterization of Targeting Molecule, Targeting Molecule-Cys, and Targeting Molecule-Cy7

[0185] 1. Synthesis and characterization of targeting molecules and targeting molecule-Cys

[0186] The pHA-VAP peptide (amino acid sequence: p-hydroxybenzoic acid-Ahx-Cys-pavrtns; capital letters represent L-configuration amino acids, and lowercase letters represent D-configuration amino acids) was designed and synthesized by solid phase peptide synthesis.

[0187] Specific method: First, Cys(Trt)-Acp-4-tert-butylbenzoic acid was synthesized by Fmoc solid phase peptide synthesis method, and amino acids were connected in sequence on PAM-Fmoc resin, and the reaction was carried out with HBTU / DIEA as condensing agent and TFA as deprotecting agent. Then, the side chain carboxyl group was activated with N-hydroxysuccinimide (NHS), and the VAP peptide synthesized by Boc protection solid phase peptide synthesis method was grafted onto cys(trt)-acp-4-tert-butylbenzoic acid, and pHA-VAP-Cys was obtained by 95% TFA deprotection. The crude polypeptide was separated and purified by acetonitrile / water (containing 0.1% TFA) system. HPLC and ESI-MS were used to characterize the purity and molecular weight (Mw) of pHA-VAP-Cys. The HPLC spectrum and mass spectrum of pHA-VAP-Cys are attached. Figure 1 .

[0188] 2. Synthesis and characterization of targeting molecule-Cy7

[0189] The pHA-VAP-Cys obtained in the above steps was dissolved in 0.1M PBS solution (pH7.2), and Cy7-maleimide was dissolved in DMF. After the two were mixed, they were stirred magnetically and monitored by HPLC. After the pHA-VAP-Cys reaction was complete, the reaction was stopped and purified by preparative liquid phase. The pHA-VAP-Cy7 was separated and purified by acetonitrile / water (containing 0.1% TFA) system. The pure pHA-VAP-Cy7 was obtained by freeze drying. The HPLC spectrum and mass spectrum are attached. Figure 2 .

[0190] Example 2 Preparation of pHA-VAP-imaging agent

[0191] pHA-VAP-DOTA-Gd was prepared as an example of a pHA-VAP-imaging agent. 0.1 mmol of pHA-VAP was dissolved in a phosphate buffer solution at pH 7, and 0.1 mmol of MAL-DOTA was added and stirred for 1 hour. The reaction solution was purified by preparative liquid phase and freeze-dried to obtain pHA-VAP-DOTA. The freeze-dried pHA-VAP-DOTA was dissolved in an aqueous ammonium acetate solution, and then GdCl3·6H2O was added and stirred at room temperature for 1 hour. The reaction solution was purified by preparative chromatography and freeze-dried to obtain pHA-VAP-DOTA-Gd. HPLC and ESI-MS were used to characterize the purity and molecular weight (Mw) of pHA-VAP-DOTA-Gd. The spectrum is attached. Figure 3 .

[0192] Example 3 Verification of in vitro cell targeting of targeting molecules

[0193] 1. In vitro targeting of targeting molecules to primary brain capillary endothelial cells BCEC

[0194] The brains of 4-week-old SD rats were removed after decapitation, and the cerebral cortex was quickly separated in precooled D-Hanks solution. The meninges and large blood vessels in the brain were rolled off and cut into pieces. After adding collagenase and DNase, the mixture was digested at 37°C for 90 minutes, centrifuged at 1000 rpm for 8 minutes, the supernatant was discarded, and the mixture was transferred to a 20% BSA DMEM solution, centrifuged at 1000g / min at 4°C for 20 minutes, the middle and upper liquid was discarded, the bottom microvessels were transferred to DMEM culture medium, centrifuged at 1000 rpm for 5 minutes, the microvessel segments were resuspended in DMEM culture medium containing 20% ​​fetal bovine serum, inoculated in a 12-well plate, and cultured at 37°C, 5% CO2 and saturated humidity for 24 hours, then changed to endothelial-specific culture medium containing puromycin for continued culture for 72 hours, and then changed to endothelial-specific culture medium containing cell growth factor for culture for 72 hours to obtain primary brain capillary endothelial cells.

[0195] Use DMEM culture medium containing 10% FBS to prepare a fluorescent labeled polypeptide solution with a fluorescence concentration of 5μM. Aspirate the DMEM culture medium in the 12-well plate, add the drug solution, incubate at 37℃ for 4h, and discard the fluorescein solution. Wash the plate twice with PBS, add trypsin to digest the cells, disperse the cells with DMEM culture medium and centrifuge, discard the supernatant, wash twice with PBS, and finally disperse the cells in each well in 200μL PBS and measure by flow cytometry. The results are shown in the attached Figure 4 .

[0196] 2. In vitro targeting of targeting molecules to umbilical vein endothelial cells (HUVEC)

[0197] The monolayer cultured umbilical vein endothelial cells (HUVEC cells) in the logarithmic growth phase were taken and digested with 0.25% trypsin. The single-cell suspension was prepared with DMEM culture medium containing 10% fetal bovine serum. 1×10 cells were added to each well. 5 The cells were inoculated into a 12-well culture plate with a volume of 1 mL per well. The culture plate was moved into a carbon dioxide incubator and cultured for 24 h at 37°C, 5% CO2 and saturated humidity. The same experiment was performed as above. The results of flow cytometric analysis are shown in the attached Figure 5 .

[0198] 3. In vitro targeting of targeting molecules to glioma cells U87

[0199] Take the monolayer cultured glioma cells (U87 cells) in the logarithmic growth phase and perform the same experiment as above. The results of flow cytometry analysis are attached. Figure 6 .

[0200] 4. Uptake of pHA-VAP-DOTA-Gd by HCC1806 or A549 Tumor Cells

[0201] HCC1806 or A549 cells in logarithmic growth phase were cultured in monolayers, digested with 0.25% trypsin, and prepared into single cell suspension in RPMI 1640 medium containing 10% fetal bovine serum. 5 Cells were inoculated in a 6-well culture plate, with a volume of 2 mL per well. The culture plate was moved into a carbon dioxide incubator and cultured for 24 h at 37 ° C, 5% CO2 and saturated humidity. Then, 100 μl of pHA-VAP-DOTA-Gd or DOTA-Gd solution with a concentration of 2.5 μmol / mL was added, respectively, and incubated for 4 h. Then the solution was discarded and the plate was washed twice with PBS. 0.5 mL of concentrated nitric acid was added to each well, nitrolyzed for 20 min, 4.5 mL of purified water was added, and after mixing evenly, the content of Gd in each well was determined by IC-PMS. The results are shown in the attached figure. Figure 7 .

[0202] Example 4 In vivo targeting validation of targeting molecules

[0203] 1. Detection of tissue distribution of pHA-VAP-Cys in nude mice bearing U87 subcutaneous transplanted tumor model

[0204] A subcutaneous transplant tumor model of U87 was constructed. The same dose of fluorescein-labeled pHA-VAP peptide was injected into the tail vein. The mice were killed at 30 minutes and 1, 4, and 24 hours after injection. The blood, heart, liver, spleen, lung, kidney, brain, and tumor were collected and weighed. 1 mL of distilled water was added and the tissues were homogenized. The fluorescence was measured by an ELISA instrument and quantified. The results are shown in the attached Figure 8 .

[0205] 2. Detection of tissue distribution of pHA-VAP-Cys in nude mice bearing U87 orthotopic glioma model

[0206] Resuspend the U87 cells in the logarithmic growth phase in an appropriate amount of PBS solution to a cell concentration of 1.3×10 8 / mL. Nude mice were anesthetized by intraperitoneal injection of 8% chloral hydrate solution, fixed on a brain stereotaxic instrument, and injected with 5μL of U87 cell suspension into the striatum to construct a U87 in situ brain glioma model. Equal doses of fluorescein-labeled pHA-VAP peptide were injected through the tail vein. Mice were killed at 30 minutes and 1, 4, and 24 hours after injection, and blood, heart, liver, spleen, lung, kidney, brain and tumor were collected and weighed. 1mL of distilled water was added, and the tissues were homogenized and measured by an enzyme marker for fluorescence quantification. The results are attached. Fig. 9 .

[0207] Example 5 Preparation of targeting molecule-drug complex

[0208] The pHA-VAP-doxorubicin complex was prepared as an example of a targeting molecule to connect a ketone or aldehyde-containing drug. 9.4 mg of thiolated pHA-VAP was dissolved in 3 mL of phosphate buffer (0.1 mM, pH 7.4), and an equimolar amount of doxorubicin 6-maleimidohexahydrazine derivative was added. The mixture was reacted at room temperature in the dark for 1 h. The reaction solution was purified by preparative liquid phase and freeze-dried to obtain the pHA-VAP-doxorubicin complex. HPLC spectrum and mass spectrum are attached. Fig.10 .

[0209] An example of using pHA-VAP-paclitaxel complex as a targeting molecule to connect hydroxyl or amino drugs with disulfide bonds. 200 mg of paclitaxel was dissolved in 10 mL of chloroform, cooled to 0-5°C, and 39.99 mg of DCC and 60.4 mg of 3-(2-pyridyldithiol)propionic acid were added successively. After the addition was completed, the mixture was heated to room temperature and reacted overnight. The reaction solution was filtered and purified by column chromatography (CHCl3 / MeOH=50:1-15:1, V / V elution) to obtain paclitaxel 3-(2-pyridyldithiol)propionic acid derivative. Paclitaxel 3-(2-pyridyldithiol) propionic acid derivative was dissolved in 5 mL DMF, 1.5 times molar amount of pHA-VAP-Cys was dissolved in PBS / DMF, and the pH value of the solution was maintained at 4-5. Paclitaxel 3-(2-pyridyldithiol) propionic acid derivative was added dropwise to the thiol polypeptide solution, reacted at room temperature for 6 hours, and the polypeptide-paclitaxel complex was obtained by preparative liquid phase purification and lyophilization.

[0210] An example of using pHA-VAP-bortezomib complex as a targeting molecule to connect a drug containing a boronic acid group. Amino acids are sequentially connected to the resin according to the synthesis of pHA-VAP. After all amino acid residues of the polypeptide are connected, trifluoroacetic acid removes the Boc protection of the nitrogen end. A DMF solution containing 3 times the molar amount of succinic anhydride and DIEA is added and reacted at room temperature for 30 minutes. After washing the resin, 5 times the molar amount of trimethylsilyl chloride is added to protect dopamine, and HBTU / DIEA is used as a condensation agent to react at room temperature for 1 hour. The resin is cut with HF and purified by preparative HPLC to obtain a polypeptide-dopamine derivative. In a buffer solution of pH 7.4, the pHA-VAP-dopamine derivative and bortezomib are mixed at a molar ratio of 1:1 to obtain a pHA-VAP-bortezomib complex.

[0211] The pHA-VAP-PMI fusion polypeptide is used as an example of a targeting molecule connected to a polypeptide drug. It is prepared directly by solid phase polypeptide synthesis, and the specific method is as follows: after determining the pHA-VAP-PMI polypeptide sequence, amino acids are sequentially connected in the same manner as in the preparation of pHA-VAP, and the pHA-VAP-PMI fusion polypeptide is obtained after HF cutting and purification.

[0212] Example 6 In vitro pharmacodynamics test of targeted molecule modified nano drug delivery system

[0213] 1. In vitro efficacy test of pHA-VAP-DOX on glioma cells U87

[0214] Take U87 cells in the logarithmic growth phase, digest them with 0.25% trypsin and blow them into single cells. The cells are suspended in DMEM culture medium containing 10% FBS and inoculated in a 96-well cell culture plate at a density of 3000 cells per well. The volume of each well is 0.2mL. Three wells are left with culture medium without cells as blank wells and cultured in a carbon dioxide incubator for 24h. Dilute each group of drugs sixfold in sequence with cell culture medium. Aspirate the cell culture medium in the 96-well plate, and add 200μL of a series of drug solutions to each well. Three replicate wells are set for each concentration, and three wells with only culture medium added are left as control wells. After 72 hours of culture, 20 μL of MTT reagent (5 mg / mL) was added to the experimental wells, control wells and blank wells and incubated for 4 hours. The culture medium in the wells was discarded, and 150 μL of dimethyl sulfoxide was added to each well. After shaking to fully dissolve the generated blue-purple crystals, the absorbance (A) of each well at 490 nm was measured with an enzyme-labeled instrument, and the cell survival rate was calculated according to the following formula:

[0215] Survival rate = (A 490实验孔 -A 490空白孔 ) / (A 490对照孔 -A 490空白孔 )×100%

[0216] GraphPad Prism software was used to plot the survival rate against the logarithmic value of drug concentration (see Appendix Fig.11 ), and calculate the half inhibitory concentration (IC 50 ).

[0217] 2. In vitro efficacy test of pHA-VAP-DOX on umbilical vein endothelial cells (HUVEC)

[0218] HUVEC cells in the logarithmic growth phase were used for the same experiment. The results are shown in the attached Fig.12 .

[0219] Example 7 In vivo pharmacodynamics test of targeted molecule modified drug complex

[0220] On the 7th day after the establishment of the U87 orthotopic tumor animal model, the mice were randomly divided into 8 groups, each with 10 mice. DOX, pHA-VAP-DOX, pHA-VAP and saline were injected into the tail vein every two days. The total dose of doxorubicin was 10 mg / kg, 20 mg / kg and 40 mg / kg, respectively. The peptide was converted into the amount of peptide in the pHA-VAP-DOX 40 mg / kg complex. The survival time of nude mice in each group was recorded and the survival curve was drawn (see Appendix). Fig.13 ).

[0221] Example 8 Preparation and characterization of targeted molecule modified nano drug delivery system

[0222] 1. Preparation of pHA-VAP modified lipid membrane coated cabazitaxel nanocrystals

[0223] pHA-VAP-PEG-DSPE was synthesized by the reaction of the free thiol of pHA-VAP-Cys with the maleimide contained in Mal-PEG-DSPE. Weigh 4 mg of cabazitaxel and an appropriate amount of surfactant TPGS into a 25 ml eggplant-shaped bottle, add an appropriate amount of dichloromethane to dissolve and form a film for hydration to prepare cabazitaxel nanocrystals with good dispersibility. An appropriate amount of liposome membrane material (molar ratio: HSPC: Chol: DSPE-PEG2000 = 50:45:5) was spin-dried, and the nanocrystal solution was added to hydrate the phospholipid membrane at 65°C, and the probe was sonicated for 10 minutes (120W). The morphology was observed by uranyl acetate negative staining electron microscopy. The results are shown in the attached Fig.14 .

[0224] 2. Preparation of pHA-VAP modified erythrocyte membrane coated with docetaxel / parthenolide nanocrystals

[0225] Whole blood of male ICR mice was collected and centrifuged at 1000 g / min at 4°C for 5 minutes. The upper serum and white blood cell layer were discarded. The lower red blood cells were washed with 1×PBS and then resuspended in 0.25×PBS at 4°C for 30 minutes. Hemoglobin was removed by centrifugation at 15000 g / min at 4°C for 7 minutes. The obtained light red red blood cell membrane was resuspended and stored in double distilled water, and its membrane protein concentration was detected by BCA kit; 4 mg of docetaxel, 1.2 mg of parthenolide and an appropriate amount of surfactant F127 were weighed in a 25 mL eggplant-shaped bottle, and an appropriate amount of methanol was added to dissolve the membrane and hydrate it to prepare docetaxel / parthenolide nano-eutectic with good dispersibility; 40 μL of streptavidin-PEG 3400 -DSPE PBS solution (5 mg / mL) was incubated with erythrocyte membrane vesicles obtained from 100 μL whole blood in a 37°C water bath for 30 minutes to obtain streptavidin-erythrocyte membrane vesicles. The obtained streptavidin-erythrocyte membrane vesicles were mixed with docetaxel / parthenolide nano-cocrystals and then sonicated to obtain a nano-drug delivery system of erythrocyte membrane-coated nanocrystals with surface modified streptavidin, and then 100 μL biotin-PEG was added. 2000 -VAP-pHA PBS solution (0.1 mg / mL), incubated in a 37°C water bath for 10 minutes, to obtain a pHA-VAP modified erythrocyte membrane coated with docetaxel / parthenolide nano-cocrystal drug delivery system. Particle size and potential characterization are shown in the attached Fig.15 .

[0226] Example 9 In vitro targeting of the targeting molecule-modified nano drug delivery system

[0227] 1. Uptake test of pHA-VAP modified lipid membrane coated cabazitaxel nanocrystals by umbilical vein endothelial cells HUVEC and breast cancer cells 4T1

[0228] The plating method of HUVEC and 4T1 cells is as above. The two cells of corresponding concentrations are prepared with DMEM culture medium containing 10% FBS and incubated with free cabazitaxel, cabazitaxel nanocrystals, lipid membrane-coated cabazitaxel nanocrystals, and pHA-VAP-modified lipid membrane-coated cabazitaxel nanocrystals, respectively. The DMEM culture medium in the 12-well plate is aspirated, the drug solution is added, incubated at 37°C for 4 hours, and the drug solution is discarded. The plate is washed twice with PBS solution, and trypsin is added to digest the cells. The cells are dispersed with DMEM culture medium and counted, centrifuged, and the supernatant is discarded. The cells are washed twice with PBS, and finally each well is dispersed in 100μL PBS. After ultrasonic disruption of the cells, 3 volumes of methanol are added to precipitate the protein. After centrifugation at 10000rpm for 10 minutes, the supernatant is taken and the drug content is determined by HPLC. The results are shown in the attached Fig.16 .

[0229] 2. Uptake test of docetaxel / parthenolide nanococrystals coated with pHA-VAP modified erythrocyte membrane by primary brain capillary endothelial cells BCEC, umbilical vein endothelial cells HUVEC, and glioma cells U87

[0230] The BCEC cell extraction method and the HUVEC and U87 cell plating method are as above. The corresponding concentrations of free docetaxel / parthenolide, docetaxel / parthenolide nano-cocrystals, erythrocyte membrane-coated docetaxel / parthenolide nano-cocrystals, and pHA-VAP-modified erythrocyte membrane-coated docetaxel / parthenolide nano-cocrystals are prepared with DMEM culture medium containing 10% FBS. The DMEM culture medium in the 12-well plate is aspirated, the drug solution is added, and the incubation is carried out at 37°C for 1h, and the drug solution is discarded. The plate is washed twice with PBS solution, and trypsin is added to digest the cells. The cells are dispersed with DMEM culture medium and counted, centrifuged, and the supernatant is discarded. The PBS solution is washed twice, and the cells in each well are dispersed in 100μL PBS. After ultrasonically disrupting the cells, 3 volumes of methanol are added to precipitate the protein. After centrifugation at 10000rpm for 10min, the supernatant is taken and the drug content is determined by HPLC. The results are shown in the attached Fig.17 .

[0231] Example 10 Verification of in vivo targeting of targeted molecule-modified nano drug delivery system

[0232] 1. Tissue distribution detection of pHA-VAP modified lipid membrane coated cabazitaxel nanocrystals in nude mice bearing 4T1 orthotopic breast cancer model

[0233] A 4T1 orthotopic breast cancer model was constructed. Equal doses of free cabazitaxel, cabazitaxel nanocrystals, lipid membrane-coated cabazitaxel nanocrystals, and pHA-VAP-modified lipid membrane-coated cabazitaxel nanocrystals were injected into the tail vein. Mice were killed at 2, 12, and 24 hours after injection, and blood, heart, liver, spleen, lung, kidney, brain, and tumor were collected and weighed. 1 mL of distilled water was added, and the tissues were homogenized and extracted. HPLC quantification (Appendix Fig.18 ).

[0234] 2. Tissue distribution detection of pHA-VAP modified erythrocyte membrane coated docetaxel / parthenolide nano-cocrystals in nude mice bearing U87 orthotopic brain glioma model

[0235] U87 orthotopic brain glioma model was constructed. Equal doses of free docetaxel / parthenolide, erythrocyte membrane-coated docetaxel / parthenolide nano-cocrystals, and pHA-VAP-modified erythrocyte membrane-coated docetaxel / parthenolide nano-cocrystals were injected into the tail vein, and mice were killed at 2 and 12 h after injection, and blood, heart, liver, spleen, lung, kidney, brain and brain tumor were collected and weighed. 1 mL of distilled water was added, and the tissues were homogenized, extracted twice with methyl tert-butyl ether, evaporated, and reconstituted with methanol for HPLC quantification (see Appendix Fig.19 ).

[0236] Example 11 In vitro pharmacodynamics test of targeted molecule modified nano drug delivery system

[0237] 1. In vitro efficacy study of pHA-VAP modified lipid membrane coated cabazitaxel nanocrystals

[0238] HUVEC cells or 4T1 cells in the logarithmic growth phase were used for the same experiment. The results are shown in the attached Fig. 20 .

[0239] 2. In vitro efficacy study of pHA-VAP modified erythrocyte membrane coated with docetaxel / parthenolide nano-cocrystals

[0240] HUVEC cells or U87 cells in the logarithmic growth phase were used for the same experiment. The results are shown in the attached Fig.21 .

[0241] Example 12 In vivo pharmacodynamics test of targeted molecule modified nano drug delivery system

[0242] 1. In vivo pharmacodynamics study of pHA-VAP modified lipid membrane coated cabazitaxel nanocrystals

[0243] The constructed 4T1 orthotopic breast cancer animal model. When the tumor size is 100mm 3 The mice were divided into groups at different times and injected with PBS, free cabazitaxel, cabazitaxel nanocrystals, lipid membrane-coated cabazitaxel nanocrystals, and pHA-VAP-modified lipid membrane-coated cabazitaxel nanocrystals through the tail vein, respectively. The total dose of cabazitaxel in the drug-treated group was 16 mg / kg, divided into 4 times, with an interval of two days between each administration. The long diameter (a) and short diameter (b) of the tumor were measured with a vernier caliper every other day. The tumor volume of each group of balb / c mice was calculated according to the formula, and the curve of tumor volume change over time was plotted to calculate the statistical differences between the groups. The tumor volume was calculated according to the following formula and the growth inhibition curve was plotted (see Appendix Fig. 22 ):

[0244] V 瘤体积 =0.5(a×b 2 )

[0245] After 20 days of administration, all BALB / c mice were killed by cervical dislocation, and the subcutaneous tumors were removed and weighed, and the statistical differences among the groups were calculated (see Appendix). Fig.23 ).

[0246] 2. In vivo pharmacodynamics study of pHA-VAP modified erythrocyte membrane coated with docetaxel / parthenolide nano-cocrystals

[0247] U87 orthotopic brain glioma animal model was constructed. PBS (pH 7.4), free docetaxel / parthenolide, erythrocyte membrane-coated docetaxel / parthenolide nano-cocrystals, and pHA-VAP-modified erythrocyte membrane-coated docetaxel / parthenolide nano-cocrystals were injected into the tail vein 10 days after tumor inoculation. The total dose of docetaxel was 25 mg / kg, and the total dose of parthenolide was 6 mg / kg, which was a single dose. The survival time of nude mice was recorded (see Appendix). Fig.24 ).

[0248] 3. Pro-apoptosis and neovascularization inhibition assay of pHA-VAP modified lipid membrane coated cabazitaxel nanocrystals

[0249] On the second day after the administration of the drug, the tumor-bearing balb / c mice were killed and the tumor tissues were removed for fixation and made into paraffin sections or frozen sections. The inhibition of neovascularization was detected by CD31 staining, or the promotion of apoptosis was detected by TUNEL staining. The results are shown in the attached Fig.25 .

[0250] 4. Detection of apoptosis promotion, angiogenesis inhibition and tumor stem cell killing of pHA-VAP modified erythrocyte membrane coated docetaxel / parthenolide nano-cocrystals

[0251] On the 10th day after the administration, the tumor-bearing nude mice were killed and the tumor tissues were fixed and frozen sections were made. TUNEL staining, CD31 and CD133 antibody staining were used to detect the promotion of apoptosis, inhibition of angiogenesis and killing of tumor stem cells. The results are shown in the attached Fig.26 .

[0252] The applicant declares that the present invention illustrates the detailed method of the present invention through the above-mentioned embodiments, but the present invention is not limited to the above-mentioned detailed method, that is, it does not mean that the present invention must rely on the above-mentioned detailed method to be implemented. Those skilled in the art should understand that any improvement of the present invention, equivalent replacement of various raw materials of the product of the present invention, addition of auxiliary components, selection of specific methods, etc., all fall within the protection scope and disclosure scope of the present invention.

Claims

1. A whole-process targeting molecule, characterized in that: The whole-process targeting molecule is formed by covalently linking two molecules, a brain targeting molecule and a tumor targeting molecule, and can mediate the targeted delivery of imaging molecules, therapeutic drugs and nano-drug delivery systems; in, The brain targeting molecule is p-hydroxybenzoic acid pHA; The tumor targeting molecule is selected from: VAP polypeptide, S VAP peptide, D VAP polypeptide, and wherein: The VAP polypeptide is an L-configuration polypeptide, the amino acid sequence of which is SNTRVAP or an L-configuration VAP reverse polypeptide, the amino acid sequence of which is PAVRTNS; Said S The VAP polypeptide is a D-configuration VAP polypeptide, and its amino acid sequence is D S D N D T D R D V D A D P; Said D The VAP polypeptide is a D-type VAP reverse polypeptide with an amino acid sequence of D P D A D V D R D T D N D S.

2. The whole process targeting molecule according to claim 1, characterized in that: The whole-process targeting molecule can target brain capillary endothelial cells and cross the blood-brain barrier, target tumor neovascular endothelial cells and cross the blood-tumor barrier, and simultaneously target tumor mimicry blood vessels, tumor cells and tumor stem cells.

3. The whole process targeting molecule according to claim 2, characterized in that: The whole-process targeting molecule can mediate imaging molecules, therapeutic drugs and nano-drug delivery systems across the blood-brain barrier and blood-tumor barrier, target tumor-mimicking blood vessels, tumor cells and / or tumor stem cells, and achieve targeted delivery of imaging molecules, therapeutic drugs and nano-drug delivery systems to brain tumors and peripheral tumors with brain metastasis characteristics.

4. The whole process targeting molecule according to any one of claims 1 to 3, characterized in that Introducing active functional groups into the whole-process targeting molecule to construct the modified imaging molecule complex, therapeutic drug complex and targeting functional carrier material; wherein, introducing imaging molecule X into the whole-process targeting molecule to obtain the whole-process targeting molecule-X complex; Introducing therapeutic drug molecule Y into the whole-process targeting molecule to prepare the whole-process targeting molecule-Y complex; A polyethylene glycol-Z complex molecule is introduced into the whole-process targeting molecule to prepare a whole-process targeting molecule-polyethylene glycol-Z complex of a targeting functional carrier material, wherein Z is a lipophilic material molecule, a lipophilic drug molecule or a hydrophilic ligand molecule.

5. A drug complex, characterized in that The drug complex is composed of the whole-process targeting molecule and imaging molecule and therapeutic drug according to any one of claims 1 to 3.

6. The drug complex according to claim 5, characterized in that Active functional groups are introduced into the whole-process targeting molecule to construct the modified imaging molecule complex and therapeutic drug complex; wherein, imaging molecule X is introduced into the whole-process targeting molecule to obtain the whole-process targeting molecule-X complex; therapeutic drug molecule Y is introduced into the whole-process targeting molecule to obtain the whole-process targeting molecule-Y complex.

7. The whole process targeting molecule according to claim 4, characterized in that: In the whole-process targeting molecule-X complex, X is selected from one or more of the following: optical imaging molecules, magnetic resonance imaging agents, radionuclide imaging agents, and is used for imaging diagnosis and tracing of brain tumors or peripheral tumors.

8. The drug complex according to claim 6, characterized in that In the whole-process targeting molecule-X complex, X is selected from one or more of the following: optical imaging molecules, magnetic resonance imaging agents, radionuclide imaging agents, and is used for imaging diagnosis and tracing of brain tumors or peripheral tumors.

9. The whole process targeting molecule according to claim 7, characterized in that: The optical imaging molecules are selected from one or more of the following: fluorescent probe molecules FITC, FAM, 6-TET, 5-TAMRA, HEX, 6-JOE, near-infrared dye molecules Cy3, Cy3.5, Cy5, Cy5.5, Cy7, IR783, IR820, DiR, DiD, BIDIPY630 / 650-X, BIDIPY650 / 665-X, BIDIPY665 / 676, TO-PRO-3, TO-PRO-5, chemiluminescent substances luminol, isoluminol, AMPPD, CSPD, CDP-star, lucigenin, Raman probe molecules; The magnetic resonance imaging agent is a chelate of a Gd magnetic resonance substance; and / or The radionuclide imaging agent is selected from one or more of the following: 18 F. 32 P. 35 S. 64 Cu, 67 / 68 Ga, 75 Se, 89 Zr, 86 Y. 99m Tc, 111 / 111m In, 123 / 125 I. 177 Lu, 149 / 161 Chelated radionuclides for Tb imaging.

10. The drug complex according to claim 8, characterized in that The optical imaging molecules are selected from one or more of the following: fluorescent probe molecules FITC, FAM, 6-TET, 5-TAMRA, HEX, 6-JOE, near-infrared dye molecules Cy3, Cy3.5, Cy5, Cy5.5, Cy7, IR783, IR820, DiR, DiD, BIDIPY630 / 650-X, BIDIPY650 / 665-X, BIDIPY665 / 676, TO-PRO-3, TO-PRO-5, chemiluminescent substances luminol, isoluminol, AMPPD, CSPD, CDP-star, lucigenin, Raman probe molecules; The magnetic resonance imaging agent is a chelate of a Gd magnetic resonance substance; and / or The radionuclide imaging agent is selected from one or more of the following: 18 F. 32 P. 35 S. 64 Cu, 67 / 68 Ga, 75 Se, 89 Zr, 86 Y. 99m Tc, 111 / 111m In, 123 / 125 I. 177 Lu, 149 / 161 Chelated radionuclides for Tb imaging.

11. The whole process targeting molecule according to claim 9, characterized in that: The magnetic resonance imaging agent and radionuclide imaging agent are composed of a bifunctional chelating agent and a magnetic resonance imaging substance or an imaging radionuclide; wherein the bifunctional chelating agent is selected from one or more of the following: DOTA, DOTAGA, NOTA, NOTAGA, NODA, DTPA, TETA, CB-TE2A, Cyclam, DFO, MAG3, EC, EDTA, DADT, HYNIC, CE-DTS, NS3, and is used to chelate the magnetic resonance imaging substance or the radionuclide.

12. The drug complex according to claim 10, characterized in that The magnetic resonance imaging agent and radionuclide imaging agent are composed of a bifunctional chelating agent and a magnetic resonance imaging substance or an imaging radionuclide; wherein the bifunctional chelating agent is selected from one or more of the following: DOTA, DOTAGA, NOTA, NOTAGA, NODA, DTPA, TETA, CB-TE2A, Cyclam, DFO, MAG3, EC, EDTA, DADT, HYNIC, CE-DTS, NS3, and is used to chelate the magnetic resonance imaging substance or the radionuclide.

13. The whole process targeting molecule according to claim 4, characterized in that: In the whole-process targeting molecule-Y complex, Y is selected from one or more of the following: anthracyclines, taxanes, camptothecins, vinblastines, proteasome inhibitors, anti-tumor stem cell drugs, molecular targeted drugs, polypeptide drugs, antibody drugs, and therapeutic radionuclide chelates in tumor chemotherapy drugs.

14. The drug complex according to claim 6, characterized in that In the whole-process targeting molecule-Y complex, Y is selected from one or more of the following: anthracyclines, taxanes, camptothecins, vinblastines, proteasome inhibitors, anti-tumor stem cell drugs, molecular targeted drugs, polypeptide drugs, antibody drugs, and therapeutic radionuclide chelates in tumor chemotherapy drugs.

15. The whole process targeting molecule according to claim 13, characterized in that: The anthracycline drugs in the tumor chemotherapy drugs are selected from one or more of the following: doxorubicin, epirubicin; The taxane drugs are selected from one or more of the following: paclitaxel, docetaxel, cabazitaxel; The camptothecin drug is selected from one or more of the following: camptothecin, hydroxycamptothecin, 9-nitrocamptothecin, irinotecan; The vinca alkaloid drug is selected from one or more of the following: vinblastine, vincristine; The proteasome inhibitor drug is bortezomib; The anti-tumor stem cell drugs are selected from parthenolide and its derivatives; The molecular targeted drugs are selected from one or more of the following: trametinib, imatinib, nilotinib, dasatinib, everolimus, erlotinib, sunitinib, sorafenib, ibrutinib, regorafenib, vemurafenib, olaparib; and / or The polypeptide drug is selected from one or more of the following: p53 activation peptide, bee venom peptide, scorpion venom peptide, antimicrobial peptide; The antibody drug is selected from one or more of the following: rituximab, bevacizumab, trastuzumab, cetuximab, pertuzumab, ipilimumab, nivolumab, PD-L1 monoclonal antibody, and combinations of antibody fragments modified by genetic engineering including Fab fragments, single domain antibodies, Fv fragments, single chain antibodies, bivalent small molecule antibodies, mini antibodies, nano antibodies; and / or The therapeutic radionuclide chelate is selected from one or more of the following: 90 Y. 131 I. 152 / 155 Tb, 153 Sm, 177 Lu, 186 / 188 Re, 211 At 212 / 213 Bi, 212 Pb, 225 Ac, 227 Chelated Th therapeutic radionuclides.

16. The drug complex according to claim 14, characterized in that: The anthracycline drugs in the tumor chemotherapy drugs are selected from one or more of the following: doxorubicin, epirubicin; The taxane drugs are selected from one or more of the following: paclitaxel, docetaxel, cabazitaxel; The camptothecin drug is selected from one or more of the following: camptothecin, hydroxycamptothecin, 9-nitrocamptothecin, irinotecan; The vinca alkaloid drug is selected from one or more of the following: vinblastine, vincristine; The proteasome inhibitor drug is bortezomib; The anti-tumor stem cell drugs are selected from parthenolide and its derivatives; The molecular targeted drugs are selected from one or more of the following: trametinib, imatinib, nilotinib, dasatinib, everolimus, erlotinib, sunitinib, sorafenib, ibrutinib, regorafenib, vemurafenib, olaparib; and / or The polypeptide drug is selected from one or more of the following: p53 activation peptide, bee venom peptide, scorpion venom peptide, antimicrobial peptide; The antibody drug is selected from one or more of the following: rituximab, bevacizumab, trastuzumab, cetuximab, pertuzumab, ipilimumab, nivolumab, PD-L1 monoclonal antibody, and combinations of antibody fragments modified by genetic engineering including Fab fragments, single domain antibodies, Fv fragments, single chain antibodies, bivalent small molecule antibodies, mini antibodies, nano antibodies; and / or The therapeutic radionuclide chelate is selected from one or more of the following: 90 Y. 131 I. 152 / 155 Tb, 153 Sm, 177 Lu, 186 / 188 Re, 211 At 212 / 213 Bi, 212 Pb, 225 Ac, 227 Chelated Th therapeutic radionuclides.

17. The whole process targeting molecule according to claim 15, characterized in that: The therapeutic radionuclide chelate is composed of a bifunctional chelator and a therapeutic radionuclide, wherein the bifunctional chelator is selected from DOTA, DOTAGA, NOTA, NOTAGA, NODA, DTPA, TETA, CB-TE2A, Cyclam, DFO, MAG3, EC, EDTA, DADT, HYNIC, CE-DTS, and NS3.

18. The drug complex according to claim 16, characterized in that The therapeutic radionuclide chelate is composed of a bifunctional chelator and a therapeutic radionuclide, wherein the bifunctional chelator is selected from DOTA, DOTAGA, NOTA, NOTAGA, NODA, DTPA, TETA, CB-TE2A, Cyclam, DFO, MAG3, EC, EDTA, DADT, HYNIC, CE-DTS, and NS3.

19. A targeting functional carrier material, characterized in that: The targeting functional carrier material is composed of the full-process targeting molecule described in any one of claims 1 to 3 and a polymer carrier material.

20. The targeting functional carrier material according to claim 19, characterized in that: An active functional group is introduced into the whole-process targeting molecule to construct a polymer carrier material complex modified by the whole-process targeting molecule; wherein, a polyethylene glycol-Z complex molecule is introduced into the whole-process targeting molecule to obtain a targeting functional carrier material whole-process targeting molecule-polyethylene glycol-Z complex, wherein Z is a lipophilic material molecule or a lipophilic drug molecule or a hydrophilic ligand molecule.

21. The whole process targeting molecule according to claim 4, characterized in that: The lipophilic material molecule Z is selected from one or more of the following: phospholipids, polylactic acid PLA, lactic acid-glycolic acid copolymer PLGA, polycaprolactone PCL; The lipophilic drug molecule Z is selected from one or more of the following: anthracyclines, taxanes, camptothecins, vinca alkaloids, proteasome inhibitors, lactone anti-tumor drugs; and / or The hydrophilic ligand molecule Z is biotin.

22. The targeting functional carrier material according to claim 20, characterized in that: The lipophilic material molecule Z is selected from one or more of the following: phospholipids, polylactic acid PLA, lactic acid-glycolic acid copolymer PLGA, polycaprolactone PCL; The lipophilic drug molecule Z is selected from one or more of the following: anthracyclines, taxanes, camptothecins, vinca alkaloids, proteasome inhibitors, lactone anti-tumor drugs; and / or The hydrophilic ligand molecule Z is biotin.

23. Use of the whole-process targeting molecule according to claim 21 or the targeting functional carrier material according to claim 22 in the preparation of a nano drug delivery system, wherein: When the lipophilic material molecule Z is a phospholipid, the whole-process targeting molecule or the targeting functional carrier material is used to prepare a liposome drug delivery system, a micelle drug delivery system or a disc drug delivery system; When the lipophilic material molecule is selected from polylactic acid complex, lactic acid-co-glycolic acid copolymer and / or polycaprolactone, the whole process targeting molecule or targeting functional carrier material is used to prepare micelle drug delivery system or nanoparticle drug delivery system; and / or When the hydrophilic ligand molecule Z is biotin, the whole-process targeting molecule or targeting functional carrier material is used to prepare a biofilm-coated nano drug delivery system.

24. The use according to claim 23, characterized in that The liposome drug-carrying system, micelle drug-carrying system, disc drug-carrying system, nanoparticle drug-carrying system and biofilm-coated nano drug-carrying system are used for encapsulating diagnostic drugs and for imaging diagnosis and tracing of brain tumors or peripheral tumors.

25. The use according to claim 24, characterized in that The diagnostic drug is selected from one or more of the following: optical imaging substances, magnetic resonance imaging agents, and radionuclide imaging agents.

26. The use according to claim 25, characterized in that The optical imaging substance is selected from one or more of the following: fluorescent probes coumarin 6, FITC, FAM, DiI, Rhodamine B, Rhodamine6G, 5-TAMRA, 6-TET, HEX, 6-JOE, near-infrared dyes Cy3, Cy3.5, Cy5, Cy5.5, Cy7, IR783, IR820, DiR, DiD, Alexa Fluor 680, BIDIPY630 / 650-X, BIDIPY650 / 665-X, BIDIPY665 / 676, TO-PRO-3, TO-PRO-5, chemiluminescent substances luminol, isoluminol, AMPPD, CSPD, CDP-star, lucigenin, and Raman probes.

27. The use according to claim 25, characterized in that The magnetic resonance imaging agent is a chelate of Gd magnetic resonance imaging substance.

28. The use according to claim 25, characterized in that The radionuclide imaging agent is selected from one or more of the following: 18 F. 32 P. 35 S. 64 Cu, 67 / 68 Ga, 75 Se, 89 Zr, 86 Y. 99m Tc, 111 / 111m In, 123 / 125 I. 177 Lu, 149 / 161 Chelated radionuclides for Tb imaging.

29. The use according to any one of claims 23 to 28, characterized in that The liposome drug delivery system, micelle drug delivery system, disc drug delivery system, nanoparticle drug delivery system and biofilm-coated nano drug delivery system are used to encapsulate tumor therapeutic drugs and are used for targeted treatment of brain tumors or peripheral tumors with brain metastasis characteristics.

30. The use according to claim 29, characterized in that The tumor treatment drug is selected from one or more of the following: anthracyclines in chemotherapy, taxanes, camptothecins, vinblastines, platinum drugs, proteasome inhibitors, anti-tumor stem cell drugs, molecular targeted drugs, polypeptide drugs, antibody drugs, and therapeutic radionuclide chelates.

31. The use according to claim 30, characterized in that: The anthracycline drugs in the chemotherapy are selected from one or more of the following: doxorubicin, epirubicin; The taxane drugs are selected from one or more of the following: paclitaxel, docetaxel, cabazitaxel; The camptothecin drug is selected from one or more of the following: camptothecin, hydroxycamptothecin, 9-nitrocamptothecin, irinotecan; The vinca alkaloid drug is selected from one or more of the following: vinblastine, vincristine; The platinum drug is selected from one or more of the following: cisplatin, carboplatin, oxaliplatin, miplatin; The proteasome inhibitor drug is selected from one or more of the following: bortezomib, carfilzomib; The anti-tumor stem cell drugs are selected from one or more of the following: parthenolide and its derivatives; The molecular targeted drug is selected from one or more of the following: trametinib, imatinib, nilotinib, dasatinib, everolimus, erlotinib, sunitinib, sorafenib, ibrutinib, regorafenib, vemurafenib, olaparib; The polypeptide drug is selected from one or more of the following: p53 activation peptide, bee venom peptide, scorpion venom peptide and antimicrobial peptide; The antibody drugs are selected from one or more of the following: rituximab, bevacizumab, trastuzumab, cetuximab, pertuzumab, ipilimumab, nivolumab, PD-L1 monoclonal antibody, and combinations of antibody fragments modified by genetic engineering methods, including Fab fragments, single domain antibodies, Fv fragments, single chain antibodies, bivalent small molecule antibodies, mini antibodies, and nano antibodies; and / or The therapeutic radionuclide chelate is selected from one or more of the following: 90 Y. 131 I. 152 / 155 Tb, 153 Sm, 177 Lu, 186 / 188 Re, 211 At 212 / 213 Bi, 212 Pb, 225 Ac, 227 Chelated Th therapeutic radionuclides.

32. A nano drug delivery system, characterized in that: The nano drug delivery system comprises the whole-process targeting molecule of claim 4 or the targeting functional carrier material of claim 19 or 20, and the nano drug delivery system is constructed by introducing a polyethylene glycol-Z complex into the whole-process targeting molecule, wherein Z is a lipophilic material molecule or a lipophilic drug molecule or a hydrophilic ligand molecule; The lipophilic material molecule Z is selected from one or more of the following: phospholipids, polylactic acid PLA, lactic acid-glycolic acid copolymer PLGA, polycaprolactone PCL; The lipophilic drug molecule Z is selected from one or more of the following: anthracyclines, taxanes, camptothecins, vinca alkaloids, proteasome inhibitors, lactone anti-tumor drugs; and / or The hydrophilic ligand molecule Z is biotin.

33. The nano drug delivery system according to claim 32, characterized in that: When the lipophilic material molecule Z is a phospholipid, the nano drug delivery system is a liposome drug delivery system, a micelle drug delivery system or a disc drug delivery system; When the lipophilic material molecule Z is polylactic acid, lactic acid-co-glycolic acid copolymer and / or polycaprolactone, the nano drug delivery system is a micelle drug delivery system or a nanoparticle drug delivery system; and / or When the hydrophilic ligand molecule Z is biotin, the nano drug delivery system is a biomembrane-coated nano drug delivery system.

34. The nano drug delivery system according to claim 33, characterized in that: The liposome drug-carrying system, micelle drug-carrying system, disc drug-carrying system, nanoparticle drug-carrying system and biofilm-coated nano drug-carrying system are used for encapsulating diagnostic drugs and for imaging diagnosis and tracing of brain tumors or peripheral tumors.

35. The nano drug delivery system according to claim 34, characterized in that: The diagnostic drug is selected from one or more of the following: optical imaging substances, magnetic resonance imaging agents, and radionuclide imaging agents.

36. The nano drug delivery system according to claim 35, characterized in that: The optical imaging substance is selected from one or more of the following: fluorescent probes coumarin 6, FITC, FAM, DiI, Rhodamine B, Rhodamine 6G, 5-TAMRA, 6-TET, HEX, 6-JOE, near-infrared dyes Cy3, Cy3.5, Cy5, Cy5.5, Cy7, IR783, IR820, DiR, DiD, Alexa Fluor 680, BIDIPY630 / 650-X, BIDIPY650 / 665-X, BIDIPY665 / 676, TO-PRO-3, TO-PRO-5, chemiluminescent substances luminol, isoluminol, AMPPD, CSPD, CDP-star, lucigenin, Raman probe; The magnetic resonance imaging agent is a chelate of a Gd magnetic resonance imaging substance; and / or The radionuclide imaging agent is selected from one or more of the following: 18 F. 32 P. 35 S. 64 Cu, 67 / 68 Ga, 75 Se, 89 Zr, 86 Y. 99m Tc, 111 / 111m In, 123 / 125 I. 177 Lu, 149 / 161 Chelated radionuclides for Tb imaging.

37. The nano drug delivery system according to claim 33, characterized in that: The liposome drug delivery system, micelle drug delivery system, disc drug delivery system, nanoparticle drug delivery system and biofilm-coated nano drug delivery system encapsulate tumor therapeutic drugs and are used for targeted treatment of brain tumors or peripheral tumors with brain metastasis characteristics.

38. The nano drug delivery system according to claim 37, characterized in that: The tumor treatment drug is selected from one or more of the following: anthracyclines in chemotherapy, taxanes, camptothecins, vinblastines, platinum drugs, proteasome inhibitors, anti-tumor stem cell drugs, molecular targeted drugs, polypeptide drugs, antibody drugs, and therapeutic radionuclide chelates.

39. The nano drug delivery system according to claim 38, characterized in that: The anthracycline drugs in the chemotherapy are selected from one or more of the following: doxorubicin, epirubicin; The taxane drugs are selected from one or more of the following: paclitaxel, docetaxel, cabazitaxel; The camptothecin drug is selected from one or more of the following: camptothecin, hydroxycamptothecin, 9-nitrocamptothecin, irinotecan; The vinca alkaloid drug is selected from one or more of the following: vinblastine, vincristine; The platinum drug is selected from one or more of the following: cisplatin, carboplatin, oxaliplatin, miplatin; The proteasome inhibitor drug is selected from one or more of the following: bortezomib, carfilzomib; The anti-tumor stem cell drugs are selected from one or more of the following: parthenolide and its derivatives; The molecular targeted drug is selected from one or more of the following: trametinib, imatinib, nilotinib, dasatinib, everolimus, erlotinib, sunitinib, sorafenib, ibrutinib, regorafenib, vemurafenib, olaparib; The polypeptide drug is selected from one or more of the following: p53 activation peptide, bee venom peptide, scorpion venom peptide and antimicrobial peptide; The antibody drugs are selected from one or more of the following: rituximab, bevacizumab, trastuzumab, cetuximab, pertuzumab, ipilimumab, nivolumab, PD-L1 monoclonal antibody, and combinations of antibody fragments modified by genetic engineering methods, including Fab fragments, single domain antibodies, Fv fragments, single chain antibodies, bivalent small molecule antibodies, mini antibodies, and nano antibodies; and / or The therapeutic radionuclide chelate is selected from one or more of the following: 90 Y. 131 I. 152 / 155 Tb, 153 Sm, 177 Lu, 186 / 188 Re, 211 At 212 / 213 Bi, 212 Pb, 225 Ac, 227 Chelated Th therapeutic radionuclides.

Citation Information

Patent Citations

  • Multi-purpose targeting molecule and applications thereof

    CN107029239A

  • Preparation method of active target biological membrane nano preparation

    CN108524469A

  • Whole process targeting polypeptide and application in constructing tumor targeted diagnosis delivery system

    CN109384850A